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Sporadic inclusion body myositi s (IBM) is an acquired myopathy. In 1978, Carpenter and 
co-workers for the fi rst ti me described 14 pati ents with disti nct clinical and histopatho-
logical features.1 Sporadic IBM is now recognized as the most common infl ammatory 
myopathy and one of the most important myopathies in individuals over the age of fi ft y.
Epidemiology
The minimal prevalence of sporadic IBM in 1999 in The Netherlands was esti mated at 5 
pati ents per million inhabitants. Corrected for age and gender distributi on, the preva-
lence was 16 per million for inhabitants over the age of 50 years in the Netherlands.2 
However, prevalence fi gures vary considerably in diff erent populati ons and racial 
groups. In turkey, prevalence was 0.7 per million inhabitants,3 9.8 in Japan,4 10.7 in the 
USA,5 whereas a study in Western Australia reported a prevalence of 14.9.6 Diff erences 
in the worldwide distributi on of sporadic IBM may be att ributed to diff erent diagnosti c 
criteria, recruitment procedures, and possibly to geneti c or environmental factors.
Clinical characteristi cs
The fi rst symptoms of weakness in sporadic IBM usually start aft er the age of 40, with 
an average age at onset of 60 years.2, 7 Men are 2-4 ti mes more oft en aff ected than 
women.8, 9 Muscle groups aff ected early in the course of the disease are the quadriceps 
muscles, fi nger fl exors and pharyngeal muscles. Weakness of these muscles leads to 
typical functi onal disability in pati ents: quadriceps weakness leads to buckling of the 
knees, repeti ti ve falls on the knees and diffi  culty with climbing stairs or rising from a 
chair. Weakness of the deep fi nger fl exors results in inability to make a ti ght fi st with 
nails no longer visible (Figure). Pharyngeal weakness causes swallowing dysfuncti on, 
leading to social impairment, when shared meals are avoided due to embarrassment. 
Furthermore, it can lead to weight loss due to decreased caloric intake. Prevalence 
fi gures of dysphagia in sporadic IBM diff er considerably between reported studies, 
ranging from 40-80%.9-13 the wide range in prevalence most likely originates from the 
lack of a common defi niti on of dysphagia.
In some cases, the onset of symptoms follows an atypical patt ern, presenti ng with 
extensive fi nger extensor weakness, ‘scapula alata’ or ‘dropped head syndrome’.
It is not known whether the heart, which is a non-skeletal striated muscle, is af-
fected in sporadic IBM, although it is in the other idiopathic infl ammatory myopathies, 
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polymyositis and dermatomyositis.14-17 however, data on cardiac involvement in 
polymyositis should be interpreted with caution, as the criteria used in these studies 
include the previous Bohan and Peter criteria18, 19 which may include sporadic IBM 
patients in the polymyositis category. It is therefore possible that to some extent, the 
heart in sporadic IBM is involved as well.
Although data on the distribution of muscle weakness in the early phase of the 
disease are known, this is not the case for the exact course of the disease over a 
longer period of time. The rate of progression of muscle weakness and the acquired 
functional disability have not been studied over multiple years. Sporadic IBM is consid-
ered to be slowly progressive and is thought not to shorten life-expectancy, but studies 
confirming these assumptions are lacking so far. It is unknown whether sporadic IBM 
patients die due to causes related to sporadic IBM.
Figure
Panel A showing a sporadic IBM patient unable to make a tight fist in which the nails are no longer 




Diagnosti c pitf alls
Pati ents oft en experience a considerable delay in ti me to diagnosis, illustrated by the 
following case descripti on.
A 70 year-old man presented with progressive gait unsteadiness for fi ve years. He 
had to use his arms to climb the stairs or to get up from a chair. There were no pain, 
sensory symptoms or fati gue. He had pulmonary sarcoidosis at the age of 24 years, 
which remained in remission aft er treatment with ACTH and prednisone. There was no 
family history of autoimmune or muscle diseases. Clinical examinati on showed muscle 
weakness of the iliopsoas, quadriceps and biceps brachii muscles. Gait examinati on 
was normal. Toe and heel walking were normal, but the pati ent was unable to squat. 
Further investi gati ons showed normal laboratory fi ndings, including normal creati ne 
kinase levels. Needle electromyography of the left  rectus femoris muscle showed no 
abnormaliti es. The soleus muscle showed spontaneous muscle fi ber acti vity and high 
amplitude, polyphasic motor unit acti on potenti als (MUAPs), more reminiscent of an 
axonal neuropathy than a myopathy. Biopsy of a symptomati c anterior ti bial muscle 
showed nonspecifi c myopathic changes. A possible sporadic inclusion body myositi s or 
motor neuron disease was considered as only motor dysfuncti on was found. Over the 
following years, his muscle weakness progressed and spread to the distal legs and fi nger 
fl exors of two fi ngers of the right hand. Three years later he was parti ally wheelchair 
bound. He then reported diffi  culti es with swallowing solid foods. He did not develop 
fasciculati ons, cramps, or pyramidal tract signs. A second biopsy of the vastus lateralis 
muscle showed no muscle fi bres but only fatt y ti ssue. A muscle MRI was performed 
to select an appropriate muscle for a third muscle biopsy. This showed extensive fatt y 
infi ltrati on of the shoulder, limb-girdle and leg-musculature. Muscles in the legs not 
showing fatt y infi ltrati on had a high signal on STIR, indicati ng infl ammati on. Eventu-
ally, the third biopsy of the anterior ti bial muscle showed myopathic changes including 
mononuclear infl ammatory infi ltrates with invasion of non-necroti c fi bers and rimmed 
vacuoles, supporti ng the diagnosis of sporadic inclusion body myositi s.
A delay in the diagnosis and a high rate of initi al misdiagnosis is not uncommon in spo-
radic IBM.2, 7 This may well be due to a failure to recognize the characteristi c patt ern 




Serum creatine kinase activity (sCK) levels are usually elevated only 2-5 times, but 
can be normal as well. It is not likely to find sCK levels elevated more than 10 times in 
sporadic IBM. Normal or mildly elevated sCK levels can disguise this myopathy.
Electromyography in sporadic IBM patients can reveal positive sharp waves, fibril-
lation potentials and complex repetitive discharges. Motor unit potentials sometimes 
show high amplitudes and polyphasy, incorrectly suggesting a neurogenic disorder.
Muscle biopsy plays a crucial role in the diagnostic process. To reach a definite 
diagnosis of definite sporadic IBM the biopsy must show inflammatory as well as 
degenerative changes.20-22 In some cases invasion of T-cells (inflammation) or rimmed 
vacuoles (degeneration) may be absent in a first muscle biopsy. Unfortunately repeated 
biopsies, even in patients with a high clinical suspicion for sporadic IBM, may still not 
demonstrate these features.23 Implementation of muscle MRI in the diagnostic criteria 
may appear to be useful in selected cases. A previous study reports that magnetic 
resonance imaging can be used to distinguish polymyositis from sporadic IBM.24 An-
other study showed explicit fatty changes in the flexor digitorum profundus muscle, 
sometimes preceding clinically detectable weakness in this muscle.25
In the future serum biomarkers might assist in the diagnosis, as an autoantibody 
against a muscle protein was recently identified. 26, 27
Pathogenetic considerations
The pathogenesis of sporadic IBM is as yet unclear, but several findings suggest a 
primarily immune-mediated pathway. the immune process is thought to be mediated 
by CD8+ cytotoxic T-cells, which invade non-necrotic muscle fibers that express the 
MHC-I antigen. The auto-invasive T-cells are most likely antigen-driven and clonally 
expand in situ within the muscle microenvironment.28 An upregulation of cytokines 
and chemokines can further propagate the inflammatory response by facilitating T-cell 
activity, adhesion and transmigration.29 Costimulator molecules of the B7 family are 
present on the muscle fibres that bind to their counterreceptors on the auto invasive 
t-cells.30 Apart from T-cells, infiltrates of B-cells (myeloid dendritic cells and plasma 
cells) are also found. Inflammation is more obvious than other pathological hallmarks 
of the disease such as the rimmed vacuoles or amyloid depositions.31 In sporadic IBM 
patients an overrepresentation of paraproteinemias is present32 and there is an as-
sociation with other autoimmune diseases, 9, 33, 34 indicating that these patients might 
be more prone to autoimmune processes. Furthermore, genetic susceptibility studies 




8.1 MHC ancestral haplotype in the Caucasian populati on35 and the 52.1 ancestral 
haplotype in the Japanese.36
The lack of a long-lasti ng eff ect of immunomodulati ng therapy on the progression of 
the disease opts for a primary degenerati ve pathway. Proponents of this theory point 
at the presence of rimmed vacuoles and accumulati on of degenerati ve proteins, such 
as β-amyloid en phosphorylated tau protein. It is thought that rimmed vacuoles are 
derived from the breakdown of myonuclei, as the vast majority of rimmed vacuoles 
contain nuclear membrane proteins.37 the discovery of the nucleic protein tDP-43 in 
the sarcoplasm in sporadic IBM 38-41 supports the theory of nuclear breakdown. Ac-
cumulati on of degenerati ve proteins is oft en associated with other neurodegenerati ve 
diseases. It is postulated that protein misfolding leads to the accumulati on of aber-
rant proteins. This accumulati on in turn leads to failure of diff erent cell processes, for 
instance in the lysosomal degradati on of autophagosomal material.42 An infl ammatory 
response is supposed to be secondary to this aberrant protein accumulati on. The ac-
cumulati on of neurodegenerati ve proteins in muscle fi bers is not unique to sporadic 
IBM, as it is observed in other vacuolar myopathies as well, such as oculopharyngodis-
tal myopathy. However, a feature unique to sporadic IBM is the strong infl ammatory 
response coinciding with the degenerati ve changes. A possible link between the two 
mechanisms may be found in the strong correlati on between mRNA expression of the 
amyloid precursor protein with several proinfl ammatory chemokines and interleukins. 
Upregulati on of the amyloid precursor protein and subsequently accumulati on of 
β-amyloid was seen in human myotubes exposed to IL-1β.43 this suggests that in a 
sporadic IBM muscle the presence of pro-infl ammatory mediators causes β-amyloid 
aggregati on. Besides an upregulati on of the amyloid precursor protein in IL-1β ex-
posed human myotubes, αB-crystalline (a stressor protein) is overexpressed as well.44 
Several normal appearing muscle fi bers in sporadic IBM contain αB-crystalline and 
amyloid precursor protein before amyloid deposits or rimmed vacuoles are detected, 
suggesti ng that proinfl ammatory changes precede degenerati on. 44
Aims of this thesis
The present thesis fi rstly aims to expand the descripti on of clinical features of sporadic 
IBM. the natural history study described in Chapter 2 provides informati on about the 
course of the disease over a long ti me period and might clarify whether sporadic IBM 
infl uences life expectancy. The incidence and character of dysphagia, a symptom oft en 
present in sporadic IBM, is investi gated in a standard manner, using a standardized 
ChAPtER 1
14
questionnaire and by performing a swallowing video fluoroscopy in Chapter 3. Pos-
sible involvement of the heart in sporadic IBM is studied in a cross sectional setting in 
Chapter 4. MRI of skeletal muscles is described in Chapter 5 aiming at specific patterns 
of abnormalities in sporadic IBM compared to other myopathies, hence contributing to 
a better diagnostic process. Finally, we investigated the role of TREX1, a gene strongly 
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Chapter 2
A 12-year follow-up in sporadic 
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Sporadic inclusion body myositis is considered to be a slowly progressive myopathy. 
Long-term follow-up data are, however, not yet available. Follow-up data are impor-
tant with a view to informing patients about their prognosis and selecting appropriate 
outcome measures for clinical trials. We performed a follow-up study of 64 patients 
with sporadic inclusion body myositis who participated in a national epidemiological 
study in the Netherlands. Case histories were recorded, and manual and quantita-
tive muscle tests as well as laboratory tests were performed at baseline and 12 years 
(median) after the first out-patient visit. Date and cause of death were recorded for 
all deceased patients. Forty-six patients died during the follow-up period, two patients 
chose not to participate and one patient was lost to follow-up. The remaining fifteen 
surviving patients had a mean disease duration of 20 years and were clinically evalu-
ated at the second time point. The mean decline in strength was 3.5% and 5.4 % per 
year according to manual muscle testing and quantitative muscle testing, respectively. 
this decline was most pronounced in the lower legs, which were also the weakest 
extremities. Life expectancy was normal at 81 years, but activities of daily life were 
clearly restricted. At follow-up, all patients were found to be using a wheelchair, 7 of 
them (47%) being completely wheelchair-bound. Disorders of the respiratory system 
were the most common cause of death. In three patients euthanasia was requested 
and in another three, continuous deep sedation was applied. The fact that end-of-life 
care interventions were used in 6 patients (13%) reflects the severe disability and loss 
of quality of life at the end-stage of this disease.
Sporadic inclusion body myositis is a chronic progressive disorder, leading to major 
disabilities at the end-stage of the disease due to extensive muscle weakness.
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Introducti on
Sporadic inclusion body myositi s (IBM) is rare, but is nevertheless thought to be the 
most frequently occurring, acquired, progressive myopathy aff ecti ng pati ents over 
fi ft y years of age.1 It is considered to be a slowly but steadily progressive disease, 
which does not interfere with life expectancy.2, 3
Data on the clinical course of sporadic IBM are limited. Although two retrospecti ve 
studies 4, 5 and 2 prospecti ve studies 6, 7 have been published, these investi gated small 
cohorts with a short follow-up period. the rate of decline of muscle strength reported 
in these studies showed a large variati on. Small studies do not allow the identi fi cati on 
of prognosti c factors, although one did fi nd a possible associati on between being posi-
ti ve for human leucocyte anti gen (HLA) DR3 and a faster decline in quadriceps strength 
in 6 pati ents.8
A larger natural history study in sporadic IBM with long-term follow-up provides 
important data for multi ple reasons. Firstly, pati ents can be bett er informed about 
the expected course of their disease. Secondly, possible infl uencing factors, such as 
hLA, might provide more insight into disease pathology. thirdly, when planning future 
trials, these data might help in the selecti on of appropriate outcome measures and 
enable power calculati ons.
We conducted a follow-up study of 64 pati ents with sporadic IBM over a period 
of 10 to 13 years, focusing on decline in muscle strength, functi onal status and life 
expectancy.
Pati ents and Methods
Pati ents
From 1996-2000, 64 pati ents fulfi lling the European Neuromuscular Centre criteria9 
for defi nite (n = 58) or probable (n = 6) sporadic IBM parti cipated in a cross-secti onal 
nati onwide study, which resulted in a descripti on of the clinical characteristi cs of the 
disease.10 A subgroup of 44 pati ents also parti cipated in a clinical trial comparing 
weakness progression during 48 weeks of treatment with methotrexate or placebo, 
which showed no stati sti cal diff erence. 11
All pati ents were invited to parti cipate in the present study. For those who had died 
since the initi al assessment, the date and cause of death were retrieved from their 
medical records by contacti ng their general practi ti oner or the treati ng physician in 




The surviving patients underwent investigations following the same protocol as the first 
assessment.10 These included recording case history, manual muscle testing (MMT) of 
32 muscle groups according to the six-point British Medical Research Council (MRC) 
scale12 and quantitative muscle testing (QMT) of 14 muscle groups using a hand-held 
myometer,13 resulting in a sum score. Three functional grading scales were completed. 
Both the Barthel index,14 a measure of physical disability ranging from 0-20 and the 
Rivermead mobility index,15 a measure of disability related to mobility ranging from 
0-15 were used - a lower score representing poorer function. The Brooke’s functional 
grading scale,16 a motor function measure scale ranging from 3-23 where 23 is the 
worst score, was also applied. Furthermore, a standardized questionnaire dealing with 
dysphagia17 was administered. the type of dysphagia was subdivided into symptoms 
of impaired propulsion or aspiration.18
HLA typing was performed at baseline in 53 of these 64 patients by a complement-
dependent lymphocytotoxicity technique using locally prepared sets of anti-HLA al-
losera and monoclonal antibodies. A few patients were also typed using DNA-based 
methods.19
The study was approved by the Ethics Committee of the Leiden University Medical 
Centre and all patients gave informed consent.
Statistics
Descriptive measures were presented as mean ± standard deviation if appropriate, 
otherwise as median ± interquartile range. The paired-samples t-test was applied as a 
means of comparing the different time points, given a normal distribution; otherwise 
the Wilcoxon signed-rank test was used. For comparison between different groups 
within the cohort, an independent-samples t-test was used, or Mann-Whitney U-test 
in case of abnormal distribution. For categorical variables the Fisher’s exact test was 
used. the rates of decline in strength per year and per 10 years were calculated on 
MMT and QMT, assuming the decline was linear. Correlation tests were performed us-
ing Pearson product if appropriate or Spearman’s Rank correlation. Time to definitive 
wheelchair dependency and survival, and factors possibly influencing the latter were 
calculated using a Kaplan-Meier plot and log-rank tests. Information about Dutch life 
expectancy and causes of death were gathered from Central Statistics Office of the 
Netherlands.20 The survival curve for the general Dutch population was generated with 
adjustment for life expectancy, age at onset and gender for each individual patient. To 
compare the causes of death in our cohort with those in the general Dutch population, 
chi-squared tests were used with observed and expected values; in addition, a Bonfer-
roni correction of 14 was applied to correct for multiple comparisons, as we had 14 
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main categories. Stati sti cal analyses were carried out with SPSS for Windows 16 (SPSS 
Inc., Chicago, IL).
Results
Pati ent characteristi cs
The original, complete cohort comprised 64 Dutch pati ents with sporadic IBM (43 
males). Classifi cati on of pati ents in the various diagnosti c categories is given in 
Supplemental table 1. Pati ents, if grouped according to having defi nite or probable 
sporadic IBM, did not diff er in age at onset, age and durati on of symptoms at fi rst visit, 
functi onal grading scales and muscle testi ng scores at fi rst visit. Therefore, they are 
presented as a single group. At follow-up, 46 pati ents had died, one pati ent was lost 
to follow-up and 17 pati ents were sti ll alive (12 males). Of these, one male declined to 
Table 1. Characteristi cs of pati ents
Complete cohort Deceased pati ents Surviving pati ents p-value†
Number of pati ents 64 46 15
Male 43 31 11 0.76
Female 21 15 4
Age at 1st visit (years) 68 ± 9 71 ± 8 60 ± 8 <0.001*
Male 66 ± 8 68 ± 8 60 ± 8
Female 72 ± 10 75 ± 8 60 ± 9
Age at 2nd visit (years) - - 73 ± 8 -
Male - - 73 ± 8
Female - - 73 ± 8
Age at onset (years) 57 ± 9 58 ± 9 52 ± 9 0.03*
Symptom durati on at 1st 
visit (years)
11 (5-15) 11 (6-16) 7 (4-11) 0.06
Symptom durati on at 2nd 
visit (years)
- - 20 ± 5 -
sCK levels at 1st visit (U/l)
Male 501 (254-717) 443 (259-658) 581 (207-1310) 0.37
Female 246 (173-466) 233 (175-454) 461 (178-771) 0.31
sCK levels at 2nd visit (U/l)
Male - - 228 (106-512) -
Female - - 151 (41-317) -
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participate in this study and one female was unable to give informed consent due to 
concomitant disease. This left 15 surviving patients who were evaluated for the second 
time. The median time to follow-up was 12 years (interquartile range 11-13). Baseline 
characteristics of the cohorts of deceased or surviving patients and of the complete 
cohort are summarized in table 1. Not unexpectedly the mean age of the patients in 
the surviving cohort was significantly lower at baseline, with better scores on strength 
and functional scales. The age at onset was lower in the surviving patients compared 
to the deceased cohort.
Muscle strength
Mean decline in muscle strength by MMt was 3.5% ± 1.6 per year and 28.8% ± 11.9 
over a 10-year time period (p < 0.0005). Mean MRC score at baseline for the surviving 
15 patients was 285 ± 19 points, at follow-up this was 184 ± 52 points. The correlation 
between these two scores was 0.39.
No correlation was found between age or duration of symptoms at baseline and the 
rate of decline on MMT. No associations were found between the rate of weakness 
progression and gender, presenting symptom, HLA-B8, -DR3 or -DR53.
HLA positive (%)
B8 56 48 80 0.100
DR3 64 61 73 1.000
DR53 6 2 20 0.081
First weakness (%)
Quadriceps 63 59 80 0.247
Finger flexors 14 19 13
Pharyngeal muscles 9 11 7
Other 14 11 0
MMt 1st visit 265 (237-285) 257 (223-277) 285 (266-298) <0.001*
QMT 1st visit 2407 ± 887 2215 ± 817 2996 ± 913 0.003*
Functional grading scales 
1st visit
Barthel 19 (17-20) 18 (16-20) 20 (19-20) 0.013*
Rivermead 13 (9-14) 12 (9-13) 13 (12-14) 0.023*
Brooke’s 6 (5-8) 7 (5-8) 4 (4-6) 0.001*
Numbers in brackets represent the interquartile range.
† P-values were calculated between deceased and surviving cohort. * Significant value.
sCK = serum creatine kinase levels.
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Figure 1. Sum scores of manual muscle testi ng (MMT) and quanti tati ve muscle testi ng (QMT) and 
functi onal grading scales (Barthel index, Rivermead mobility index, Brooke’s functi onal grading 
scale) for the surviving pati ents at baseline and follow-up. All fi gures show a decline in strength 




As shown in Figure 1, the rate of decline on MMT was similar for most patients, 
except for three (patients 3, 4 and 10). One patient deteriorated more rapidly on MMT 
(9.5% per year); this was, however, partly due to a null score for his left leg because of 
an amputation for vascular obstruction. He was excluded from the strength analysis 
in order to correct for this rapid decline due to the amputation, although the rate of 
decline in his three remaining extremities was still above average (7.9% per year on 
MMT). Two other patients showed a moderate decline compared to the others (0.5% 
and 0.9% per year), without obvious reasons for it.
For QMT, the mean rates of strength decline were 5.4% ± 3.5 per year and 39.4% ± 
21.8 per 10 years (p < 0.0005). Mean score at baseline for the surviving 15 patients was 
2996 ± 913 Newton, at follow-up this was 1473 ± 753. The correlation between these 
two scores was 0.74. No factors could be identified that modulated the QMT. At follow-
up, QMT was not performed in 2 patients. One refused to undergo measurements with 
the hand-held myometer and in the other case there was a technical problem with the 
myometer. A second investigation was planned, but the patient became seriously ill 
leading to prolonged hospital admission.
The MMT and QMT scores on both visits showed good correlation (r = 0.73 and 0.92 
respectively, p = <0.001).
The pattern of selective muscle involvement was still present after a mean disease 
duration of 20 years (Figure 2a). Finger flexors, quadriceps muscles and all the muscles 
of the lower leg were most severely affected, especially compared to the relatively 
spared neck muscles, shoulder abductors and hip abductors. In the hand, the opponens 
pollicis and adductor pollicis muscles were still relatively spared, allowing patients to 
maintain some grip function, despite severely weakened flexors and extensors of the 
other fingers. Asymmetry of muscle weakness was present in all patients at follow-up.
Median decline on MMT for the quadriceps over the follow-up period was 2.5 
points on the MRC scale (interquartile range 2-4) compared to a median decline of the 
hipabductors of 1 point (interquartile range 0-2). The deep finger flexors declined with 
a median of 3.5 points (interquartile range 1-4), versus a median decline of 1 point 
(interquartile range 0-1) of the opponens pollicis (Figure 2b).
In general, sporadic IBM progresses to be a more distal myopathy (Suplementary 
Figure 1). The lower leg is weakened most severely, followed by the forearm and the 
upper leg, the upper arm and lastly the neck muscles. the rate of progression showed 
the same pattern.
Functional status
At their initial visit, the functional status of the patients was considered to be good, as 
shown by almost maximal scores on all three functional grading scales (Barthel index: 
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Figure 2 (a) Severity of muscle weakness according to Medical Research Council (MRC) scores of 
disti nct muscle groups for the surviving pati ents. The median disease durati on was 20 years. The 
fi nger fl exors, quadriceps and all the muscles of the lower legs are aff ected the most, compared to 
relati vely spared neck muscles, shoulder abductors and hip abductors. In the hand, the opponens 
pollicis and adductor pollicis muscles are relati vely spared as well. (b) Median strength decline 
according to Medical Research Council (MRC) scores of disti nct muscle groups for the surviving 
pati ents at a median disease durati on of 20 years. The largest decline in strength is seen in the 
fi nger fl exors, iliopsoas and quadriceps muscles and all muscles of the lower legs.
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20 (19-20), Rivermead mobility index: 13 (12-14), Brooke’s functional grading scale: 
4 (4-6)). However, at the second visit, all patients scored significantly worse on all 
functional grading scales as compared to baseline (Barthel index: 11 (6-16), Rivermead 
mobility index: 4 (1-9), Brooke’s functional grading scale: 13 (9-14)) (p = 0.001) (Figure 
1). These scores show that 40% of patients are completely or severely dependent (Bar-
thel index < 10), and 20% of patients are moderately dependent (Barthel index 10-15). 
No differences in the degree of deterioration were found related to age, duration of 
symptoms, gender, HLA-B8, -DR3 or -DR53 positivity. To illustrate the impact of this 
decline in functional grading scale scores, two patients with a decline comparable to 
the mean decline found in all patients are discussed in the Supplementary Material.
At baseline, a good correlation was only found between the Rivermead mobility 
index and MMT and QMT and between the Barthel index and QMT. At follow-up, all 
functional grading scales correlated well with the sum scores of the MMT and QMT.
Dysphagia was present in 12 (80%) of the surviving patients as determined by the 
use of the questionnaire. Three of them did not have dysphagia at the first visit and 
swallowing function had deteriorated in four patients. In 20% of patients, dysphagia 
was obstruction-related (e.g. food becoming stuck in throat, repetitive swallowing), in 
7% aspiration-related (choking) and mixed in 53%. Only one patient had undergone a 
cricopharyngeal myotomy resulting in a good, but temporary effect (5 years) on the 
discomforting obstructive symptoms.
At baseline, after a median disease duration of 11 years, 63 patients were living at 
home and one patient lived in a nursing home. In the surviving cohort of 15 patients, 
after a mean disease duration of 20 years, three patients were living in a nursing home 
and 12 at home with adaptations (stair lift, no thresholds, stand-up chair). Nearly all 
patients who were still living at home required considerable help with daily activities 
from their partners or other caregivers.
At baseline, 47 patients (73%) used a device to assist mobility, including nine (14%) 
who used a wheelchair. At follow-up, all 15 surviving patients used a wheelchair to 
some extent. The mean time from the first symptom to using a walking stick was 11 
± 5 years and the mean time to the first use of a wheelchair was 16 ± 4 years. Seven 
patients (47%) were completely wheelchair-bound. The median time to complete 
wheelchair dependency was 24 years. None of the patients was able to climb stairs 
any longer.
Life expectancy
Forty-six of the 64 patients died during follow-up. The median age at death was 81 
years (80 years for men, 84 years for women). In the Netherlands, life expectancy ad-
justed for gender and age at onset is 79 years (77 years for men, 83 years for women)20 
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(Figure 3), and so life expectancy was not shortened in our group of pati ents with 
sporadic IBM.
the only factor associated with life expectancy in sporadic IBM was gender, which 
is in accordance with the general Dutch populati on life expectancy, with women living 
longer than men. The presenti ng symptom (quadriceps or non-quadriceps), HLA-B8, 
-DR3 or -DR53 positi vity were not associated with a diff erent life expectancy.
The causes of death in our pati ent group are summarized in table 2 and compared to 
those in the general Dutch populati on, in the age category 80-85 years, in 2004, which 
includes the median year of death in our pati ent group.20
When compared to an age-matched general Dutch populati on, the cause of death 
in sporadic IBM pati ents was signifi cantly more oft en a disorder of the respiratory 
system, specifi cally pneumonia; this being the cause in 13 pati ents. In fi ve of these, it 
was related to aspirati on.
Cachexia, defi ned as severe wasti ng with loss of weight and muscle mass, was also 
a signifi cantly more common cause of death in pati ents with sporadic IBM than in the 
general Dutch populati on, whereas cancer was less frequent. Pati ents tended to die 
less oft en of cardiovascular diseases; however, aft er a Bonferroni correcti on, stati sti cal 
signifi cance could not be substanti ated.
Frequencies of causes of death in the general Dutch populati on in 2004 in the age 
category ranging from 70-90 years are comparable to the frequencies found in age 
category of 80-85 years.
Unfortunately, in eight pati ents the cause of death could not be further clarifi ed.
Figure 3. Kaplan-Meier curve showing a comparable survival between sporadic IBM
pati ents and an age- and sex-matched Dutch general populati on.
The curve for the general Dutch populati on is adjusted for life expectancy for each individual spo-
radic IBM (sIBM) pati ent based on the age of onset and gender.
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Euthanasia and continuous deep sedation
In six patients (13%), end-of-life care interventions were applied: three patients (6.5%) 
requested euthanasia because of unbearable suffering and severe loss of quality of life 
due to extensive weakness. The ages of death were 68, 76 and 84 years, respectively. 
Continuous deep sedation was used in three cases (6.5%), two of whom had severe 
disabling swallowing dysfunction and were dehydrated and cachectic. As they were 











Infectious diseases 1.4 2.2 0.66 ns
Neoplasms 23.8 4.3 0.002 0.03*
Diseases of blood/
bloodforming organs
0.4 0 0.67 ns
Endocrine/metabolic diseases 3.6 0 0.19 ns
Mental and behavioral 
disorders
5.6 0 0.10 ns
Diseases of the nervous 
system
2.8 2.2 0.80 ns
Diseases of the circulatory 
system
37.7 19.6 0.01 0.16
(Myocardial infarction) (7.8) (4.3)
Diseases of the respiratory 
system
11.5 41.3 0.0001* 0.001*
(Pneumonia) (4.4) (28.3)
Diseases of the digestive 
system
4.2 0 0.16 ns
Diseases of the skin 0.3 0 0.71 ns
Diseases of the bone/
connective tissue
0.7 0 0.57 ns
Diseases of the genitourinary 
system
2.8 0 0.25 ns
Cachexia 0.1 6.5 0.0001* 0.001*
External causes of injury and 
poisoning
2.1 6.5 0.04 0.51
Other/Uncertain 3.0 17.4
† Corrected P-value is calculated with a Bonferroni correction of 14. * Significant value
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completely bedridden, they chose not to feed themselves by arti fi cial means, and re-
quested conti nuous deep sedati on. The third pati ent had developed pneumonia with 
respiratory insuffi  ciency, and chose not to undergo further treatment for this infec-
ti on; conti nuous deep sedati on was applied. All three pati ents died within a day of 
the sedati on being initi ated. The ages were 73, 79 and 79, respecti vely. All six pati ents 
were completely bedridden at that ti me.
Discussion
this study illustrates that sporadic IBM is an extremely disabling disorder with normal 
life expectancy. Over a ten-year period, our pati ents lost almost one-third of muscle 
strength. All pati ents used a wheelchair and almost half of them were completely 
dependent on it. The decline in functi onal grading scale scores further refl ects the 
progressive nature of this disease. Undoubtedly, this muscle weakness resulti ng in 
functi onal disabiliti es must have a profound impact on the quality of life, as previously 
shown in a study of 60 pati ents with sporadic IBM.21
The mean ti me ti ll cane use was approximately 11 years. Peng et al showed that a 
higher age at onset is associated with earlier use of a cane.22 They found the ti me to 
use of a walker in pati ents with comparable age at onset (50-59 years) to be 8 years. 
This is somewhat shorter than described in our pati ent group. Perhaps, subjects in-
vesti gated in their study comprised more pati ents with onset with quadriceps muscle 
weakness, hence progressing earlier to the use of a walking device. Another study23 
describes cane use in 10 out of 15 pati ents aft er fi ve years.
the rate of loss of strength in the present study is lower than that found in the 
two other prospecti ve studies investi gati ng disease progression: a decline on QMT 
of 4% per six months and 14.9% per year, respecti vely.6, 7 We calculated the decline 
in strength assuming it was linear, using the two available ti me points. It is possible 
that the progression occurs more quickly at the start of the disease. However, the 
calculated rate per year in this study was within the expected range of progression of 
that of pati ents who received placebo in the methotrexate trial aft er 50 weeks from 
baseline:11 3.8 ± 5.1% in 50 weeks on MMt and 2.7 ± 10.0% on QMT respecti vely. 
Furthermore, most pati ents reported that their rate of progression did not fl uctuate 
and our clinical experience is also one of a steady course.
We found a substanti al diff erence in weakness progression between MMT and QMT 
sum scores. The mean decline in the QMT sum score was 1.5 ti mes greater than the 
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MMT sum score. The different weighing and composition of muscles scores between 
QMT and MMT is most likely the explanation.
We did not find any factors to be associated with the rate of weakness progres-
sion. The previous suggestion that HLA-DR3-positive patients possibly showed a faster 
decline than HLA-DR3-negative patients, especially in the quadriceps,8 could not be 
substantiated, possibly due to a lack of statistical power. For sufficient power, we would 
have needed at least 26 patients, but we only had 11 HLA-DR3-positive versus three 
HLA-DR3-negative patients. However, we did not see a trend towards faster decline in 
HLA-DR3-positive patients. Of the two patients showing the lowest rate of decline on 
MMT compared to the other patients, one was HLA-DR3-positive, the other negative.
The pattern of muscle weakness that developed during the disease was remarkably 
similar among patients. The lower legs demonstrated the greatest decline in strength, 
followed by the forearm and upper leg. there was a striking preference for involve-
ment of the forearm flexors, quadriceps muscles and all the lower leg muscles.
the choice of which muscle test to use for future trials is not easy. Both MMt and 
QMT show comparable rates of decline between subjects. MMT scores have smaller 
standard deviations compared to QMT and MMT is easy to apply. On the other hand, 
QMT has a better interobserver rate,24 which is important as most trials will have a 
multicenter character due to the rarity of sporadic IBM. QMT has a better correlation 
compared to MMT during follow-up. Besides, QMT will reveal small residual pareses 
more precisely than MMT. Furthermore, QMT is a continuous variable compared to 
the categorical MMT score, and therefore better to use as a sum score. We would have 
a slight preference for using QMT.
We recommend using the Brooke’s functional grading scale as the best measurement 
for functional status. This grading scale shows the most equally distributed scores at 
baseline between subjects and it shows the most comparable decline between sub-
jects over time.
Although life expectancy is not shortened in sporadic IBM, the causes of death dif-
fer from an age-matched Dutch general population. Death caused by disorders of the 
respiratory system, especially (aspiration) pneumonia, was significantly more frequent 
in our patient group. Two other studies have also identified aspiration pneumonia to 
be a common cause of death in sporadic IBM.22, 25 the high rate of respiratory disorders 
may be due to both aspiration due to pharyngeal muscle weakness25 and weakness of 
respiratory muscles.26-28
Furthermore, a significant proportion of patients died of cachexia, illustrating the 
impact of dysphagia and muscle wasting at the end-stage of the disease. An interesting 
finding was that compared to the general population, cancer was less frequently a 
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cause of death in pati ents with sporadic IBM. The diff erence may be explained by a 
failure to detect cancer due to the severity of sporadic IBM symptoms.
An unexpectedly high incidence of euthanasia and conti nuous deep sedati on was found 
in our pati ent group. In 2002, an act came into eff ect in the Netherlands, regulati ng the 
ending of life at the request of a pati ent, by a physician, if unbearable suff ering has been 
established. All six pati ents met the stringent criteria used to guarantee proper applica-
ti on of this legislati on. In 2005, 0.8% of all deaths in pati ents older than 80 years in the 
Netherlands were the result of euthanasia, and in 5.4% conti nuous deep sedati on was 
used).29 A study investi gati ng the incidence of euthanasia and conti nuous deep sedati on 
in pati ents with amyotrophic lateral sclerosis, clearly a devastati ng disease, showed that 
in 17% of Dutch pati ents with amyotrophic lateral sclerosis euthanasia was applied and 
conti nuous deep sedati on in 3%.30 The high frequency of euthanasia and conti nuous deep 
sedati on (13% in total) in sporadic IBM, about one third of the rate found in amyotrophic 
lateral sclerosis, highlights the heavy disease burden in the fi nal stage.
A limitati on of this study is the fact that a large number of the pati ents had died 
prior to follow-up examinati on. It is possible that the disease course was more severe 
in these pati ents, leading to an underesti mati on of the mean rate of progression for 
the whole group. Not unexpectedly, the pati ents who died, were signifi cantly older 
and were more severely aff ected based on the results of the functi onal grading scales 
and muscle testi ng. The deceased pati ents had a normal survival, therefore the rate of 
weakness progression was not likely to be much higher.
At baseline, the surviving pati ents were younger, had a lower age at onset and also 
showed a trend for a shorter disease durati on at ti me of diagnosis. This is a logical conse-
quence of the study methods, as younger pati ents, who already had a defi nite diagnosis 
of sporadic IBM were of course more likely to be sti ll alive at the second ti me point.
Three surviving pati ents had used prednisone 5 mg once daily for several years due 
to a concomitant autoimmune disease. the calculated decline in strength per year on 
MMT, for example, was diverse between these three pati ents, ranging from 0.5% to 
4.8%, and fell within the range of the individuals who did not use prednisone. there-
fore, we do not think this therapy had a substanti al eff ect on the natural history in 
these pati ents.
this study shows that sporadic IBM is a severe disease, in which ongoing progression 
of muscle weakness leads to signifi cant disabiliti es and a sustained disease burden. 
Pati ents have a normal life expectancy, but death as a result of sporadic IBM is oft en 
due to respiratory disorders. Whether these respiratory disorders are worsened by 
venti latory muscle weakness and if non-invasive venti lati on can improve quality of 






A male patient developed symptoms of quadriceps weakness at the age of 54. He 
noticed some difficulties with climbing stairs. At first evaluation, with disease duration 
of 11 years, he had to use his arms to pull himself up when climbing stairs and could 
not walk outside without a walking device. Mild swallowing dysfunction was present, 
with repetitive swallowing on solid foods, not influencing his eating habits. At follow-
up, after disease duration of 22 years, he was completely wheelchair bound, unable 
to lift his arms above the head and he choked when eating on a daily basis. For every 
daily activity he needed assistance from his wife. They lived at home with adaptions.
Case 2
A female patient, aged 59 years when she developed dysphagia, was evaluated for 
the first time 7 years after the onset of symptoms. At first visit, she had to swallow 
repetitively to get rid of food with every meal, without choking. There were only minor 
restrictions concerning her mobility; she was able to climb stairs, but running was im-
paired. She was completely independent in her daily activities. At follow-up, 14 years 
later, she had severe swallowing dysfunction, with worsened repetitive swallowing and 
choking, leading to prolonged duration of meals. She could walk inside the (adjusted) 
house with leg braces and a walking cane, and used a wheelchair for outside. As she 
remained ambulant to some extent, she did not become fully dependant in her daily 
functioning, although every activity was very time consuming.
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Supplemental Figure 1. Distributi on of mean manual muscle testi ng (MMT) sum scores
of the surviving pati ents per extremity part. Measurements were done at baseline (T1)
and follow-up (T2). Boxes represent median with interquarti le range; whiskers represent
minimum and maximum values. At follow-up, severity of weakness is most prominent in
the lower legs, followed by the forearm and the upper legs. the rate of strength decline
follows this same patt ern per extremity part.
Supplemental Table 1. Number of pati ents divided within the categories of the European Neuro-
muscular Centre diagnosti c criteria
Category Characteristi cs Number of pati ents (%)
Defi nite sporadic IBM 1,2,3,4,5,6 48 (75)
1,3,4,5,6,7 10 (16)*




2. Weakness of the forearm, fl exors>extensors
3. Slowly progressive disease
4. Sporadic disease
Histopathological characteristi cs
5. Mononuclear invasion of non-necroti c muscle fi bers
6. Rimmed vacuoles
7. Tubulofi lamentous structures on electron microscopy
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Dysphagia is an important yet inconsistently recognized symptom of sporadic inclusion 
body myositis (IBM). It can be disabling and potentially life-threatening. We studied 
the prevalence and symptom-sign correlation of dysphagia. Fifty-seven sporadic IBM 
patients were interviewed using a standard questionnaire for dysphagia and 43 of 
these underwent swallowing video fluoroscopy (VFS). Symptoms of dysphagia were 
present in 37 of 57 patients (65%). Nevertheless, only 17 of these patients (46%) had 
previously and spontaneously complained about swallowing to their physician. Both 
symptoms of impaired propulsion (59%) and aspiration-related symptoms (52%) were 
frequently mentioned. Swallowing abnormalities on VFS were present in 34 of 43 pa-
tients (79%) with impaired propulsion of the bolus in 77% of this group. The reported 
feeling of impaired propulsion was confirmed by VFS in 92% of these patients.
Dysphagia in sporadic IBM is common but underreported by the vast majority of 
patients if not specifically asked for. In practice, two questions reliably predict the 
presence of impaired propulsion on VFS: ‘Does food get stuck in your throat’ and ’Do 
you have to swallow repeatedly in order to get rid of food’. These questions are an 
appropriate means in selecting patients with sporadic IBM for further investigation 
through VFS and eventual treatment.
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Introducti on
Dysphagia is one of the main clinical features of sporadic inclusion body myositi s 
(IBM).1-5 Together with weakness of quadriceps and fi nger fl exor muscles, dysphagia 
consti tutes a clue for the diagnosis. It may even be the presenti ng symptom.4, 6-8 
Dysphagia causes both social embarrassment and life threatening complicati ons. It 
may lead to avoidance of shared meals and social isolati on due to audible degluti ti on. 
Besides, it can lead to unintended weight loss. Due to a higher incidence of aspirati on 
pneumonia, life expectancy is assumed to be shorter.9 Therapeuti cal interventi ons 
described to be eff ecti ve for dysphagia in sporadic IBM pati ents include cricopharyn-
geal myotomy, pharyngoesophageal dilatati on and swallowing exercises such as the 
Mendelsohn maneuver.9
We investi gated the prevalence and symptom-sign correlati on of swallowing dys-
functi on in a large group of sporadic IBM pati ents. Through this approach we aimed at 
fi nding specifi c questi ons which could reliably predict dysphagia in the sporadic IBM 
pati ent in order to infl uence the selecti on of pati ents who need further investi gati on 
through video fl uoroscopy (VFS) or who need therapeuti cal interventi ons.
Pati ents and Methods
Pati ents
The pati ents in this study were selected from a nati onal cohort of 86 sporadic IBM 
pati ents. The method of recruitment applied here has been described previously.10 Of 
these 86 pati ents, fi ve pati ents could not be located, six died prior to assessment and 
13 refrained from parti cipati on. Five pati ents were excluded because of prior cricopha-
ryngeal myotomy. This left  57 pati ents to study fulfi lling the ENMC criteria for defi nite 
(n=51) or probable (n=6) IBM.10 To evaluate recruitment bias we compared age (at 
onset), sex and disease durati on of these 57 pati ents with those of the whole cohort 
of 86 pati ents, based on their medical records. All pati ents gave informed consent. The 
study was approved by the Ethics committ ee of the Leiden University Medical Center. 
All pati ents answered a questi onnaire and were examined by video fl uoroscopy (VFS), 
unless prevented by logisti c diffi  culti es.
Questi onnaire
Pati ents were personally interviewed by one single investi gator using a previously 
published standard questi onnaire regarding dysphagia (table 1).11
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Table 1. Results of questionnaire
Question No. % Median
Impaired propulsion-related questions
Does food get stuck in your throat?
 Yes 31 54
 No 26 46
If yes, how often per month?*
 1-5 4 13
 6-10 0 0 30
 11-30 2 6
 >30 25 81
Do you have to swallow repeatedly in order to get rid of the food?
 Yes 31 54
 No 26 46
If yes, which consistency of food?
 Fluid 0 0
 Semi-fluid 3 10
 Solid 22 71
 Both fluid and solid 6 19
If yes, how often during one bite/sip?
 1-5 28 90
 6-10 3 10 3
 >10 0 0
How often per month?*
 1-5 3 10
 6-10 0 0 30
 11-30 1 3
 >30 27 87
Do you use normal or grinded food?
 Normal 56 98
 Grinded 1 2
Aspiration-related questions
Do you choke when using solid or fluid food?
 Yes 33 58
 No 24 42
If yes, how often per month?*
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 1-5 11 33
 6-10 4 12 30
 11-30 8 24
 >30 10 30
Do you have to cough oft en during/aft er a swallow when eati ng?
 Yes 19 33
 No 38 67
If yes, how oft en per month?*
 1-5 1 5
 6-10 5 26 20
 11-30 4 21
 >30 9 47
Do you have to cough during/aft er a swallow when drinking?
 Yes 8 14
 No 49 86
If yes, how oft en per month?*
 1-5 3 37
 6-10 1 12 11
 11-30 2 25
 >30 2 25
Do you cough while lying down?
 Yes 12 21
 No 45 79
If yes, how oft en per month?*
 1-5 3 25
 6-10 1 8 30
 11-30 1 8
 >30 7 58
General questi ons
have you ever reported trouble with swallowing to a doctor 
spontaneously?
 Yes 17 30
 No 40 70
Do you someti mes suff er from heartburn?
 Yes 13 23
 No 44 77
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Dysphagia due to impaired propulsion (IP) was defined by the presence of at least 
one of the following symptoms: the feeling of food getting stuck in the throat or repeti-
tive swallowing for one bolus. Aspiration-related (AR) dysphagia was defined by the 
presence of at least one of the following symptoms: choking for more than five times 
a month or coughing related to eating, drinking or lying down.
Video fluoroscopy
Video fluoroscopy (VFS) was used to record the movements and anatomy of the 
pharynx and the cervical oesophagus in lateral view. Patients were seated upright 
with their heads in neutral position. The head was stabilized occipitally and frontally. 
Each patient successively swallowed four volumes of opaque fluid (Jopamiro), viz. 
3, 6 and 9 ml, followed by a ‘dry swallow’ (0 ml). The VFS was scored by one single 
observer who was aware of the diagnosis, but uninformed with regard to the patient’s 
clinical features. Signs were subdivided in two categories: impaired propulsion (IP) or 
aspiration-related (AR).
IP included repetitive swallowing, residue in the valleculae or piriform sinus and cri-
copharyngeal sphincter dysfunction. Sphincter dysfunction was defined by a posterior 
indentation of the sphincter, as a result of contraction of the cricopharyngeal muscle 
at the moment the pharynx was still dilated and filled with contrast.12
Aspiration was defined by fluid entering the larynx. Because inadequate epiglottal 
downward tilting (IEDT) and residues in the valleculae and/or piriform sinus are gener-
ally regarded as risk factors for aspiration,13, 14 these three signs were also considered 
Do you cough daily? (not related to swallowing/lying down)
 Yes 18 32
 No 39 68
Do you give up phlegm daily?
 Yes 28 49
 No 29 51
Does fluid come out of your nose during drinking?
 Yes 5 9
 No 52 91
If yes, how often per month?
 1-3 1 20 4
 4-6 4 80
* Multiple occurrences on one day have been counted as one occasion
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as AR signs. A normal swallow was concluded in the absence of IP or AR signs. Further-
more, the presence or absence of a Zenker’s diverti culum was recorded.
Results
Demographical and clinical characteristi cs
The mean age of the 57 pati ents was 67 ± 8 years for men (n = 41) and 71 ± 10 years for 
women (n = 16), with a mean age at onset of muscle weakness at 57 ± 9 years for men 
and 59 ± 10 years for women. Most pati ents (n= 39, 68%) presented with weakness of 
the quadriceps muscles. Dysphagia was the presenti ng symptom in four pati ents (7%), 
at a mean age of 64 years. Mean durati on of symptoms of muscle weakness was 10 
± 7 years for men and 12 ± 5 years for women. The investi gated group did not diff er 
signifi cantly from the original populati on group of 86 pati ents with regard to age (at 
onset) and disease durati on. The male sex however, was slightly over-represented in 
the investi gated group compared with the group of 86 pati ents (male to female rati o: 
2:1).
Questi onnaire (n = 57)
Thirty-seven pati ents (65%) had symptoms of dysphagia. Women reported dysphagia 
more oft en compared to men (88 vs. 56%). Of these pati ents, 26 reported both IP 
and AR symptoms (46%), seven reported symptoms of IP only (12%) and four had 
exclusively AR symptoms (7%). The vast majority of these pati ents had symptoms on 
a daily basis. Solid food was the most likely to get stuck in the throat (n= 22, 71%), yet 
only one pati ent (2%) used grinded food (table 1).
Twenty pati ents with dysphagia on the questi onnaire (54%) had not spontaneously 
disclosed swallowing complaints to a physician before.
Video fl uoroscopy (n = 43)
In 34 pati ents (79%) VFS was abnormal. Abnormal fi ndings were equally frequent in 
men and women.
Thirty-three pati ents (77%) had signs of IP (repeti ti ve swallowing (n=24, 56%), 
residues in the piriform sinus (n=19, 44%) and valleculae (n=16, 37%), cricopharyngeal 
sphincter dysfuncti on (n= 16, 37%), Figure 1).
Only one pati ent showed aspirati on during VFS; this pati ent also had repeti ti ve 
swallowing, vallecular and piriform sinus residues and IEDT. Twenty-three (53%) other 
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patients had aspiration-related signs of whom 18 (43%) had IEDT. Normal swallowing 
function was observed in nine patients.
A Zenker’s diverticulum was found in eight patients (19%). The ostium of the diver-
ticulum was invariably located just above the upper oesophageal sphincter.
Comparison between questionnaire and video fluoroscopy
In 25 patients who reported symptoms of IP, a VFS was performed. Of these, 23 had 
corresponding IP signs on VFS (positive predictive value: 0.92). The highest positive 
predictive values were calculated for the questions regarding food getting stuck in the 
throat (91%) and whether or not repeated swallows (92%) were needed. Nineteen 
patients (83%) showed repetitive swallowing, 15 (65%) had a piriform sinus residue, 
13 (57%) had a vallecular residue and 10 (44%) demonstrated sphincter dysfunction. 
Remarkably, two (8%) patients had symptoms of IP, but a normal VFS. Ten out of 33 
patients with IP signs on VFS had no symptoms of IP on questionnaire. The sensitiv-
ity of the questionnaire concerning IP was 0.70, the specificity 0.80 and the negative 
predictive value 0.44.
Figure 1. VFS showing indentation of the cricopharyngeal sphincter
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Twenty-three pati ents who underwent VFS reported AR symptoms on the questi on-
naire. Confi rmati on of aspirati on on VFS was obtained in only one pati ent. Fourteen 
(65%) other pati ents showed one or more diff erent AR signs on VFS (positi ve predicti ve 
value: 0.65). Nine out of 24 pati ents with AR signs on VFS had no symptoms of aspira-
ti on on questi onnaire. The sensiti vity concerning AR signs was 0.63, the specifi city 
0.58 and the negati ve predicti ve value 0.55.
Abnormaliti es were more frequently detected by VFS than based on the questi on-
naire scores, 79% vs. 65%.
Discussion
Dysphagia is a frequent, embarrassing and potenti ally dangerous symptom in pati ents 
with sporadic IBM. Using a questi onnaire, we aimed at making an elaborate view on 
the swallowing status of the pati ent. For analysis, we took those questi ons into ac-
count which we considered to be indicati ve of IP or aspirati on and categorized them. 
The 2 categories were made to enable correlati on between symptoms and signs.
We encountered dysphagia in 65% of our sporadic IBM pati ents aft er excluding pa-
ti ents who had undergone a cricopharyngeal myotomy. The prevalence of dysphagia in 
sporadic IBM diff ers considerably between reported studies, ranging from 40-80%.1-5 
The wide range in prevalence fi gures most likely originates from the absence of a 
universal defi niti on for dysphagia.
In the present study, 37% of our pati ents had abnormal functi on of the cricopharyn-
geal sphincter. Other investi gators described sphincter dysfuncti on in 47% to 69% of 
myositi s-pati ents.8, 15 Infl ammatory involvement of the cricopharyngeal muscle is most 
likely the basis for dysfuncti on, as has been suggested by authors who reported the 
presence of infl ammati on or rimmed vacuoles in cricopharyngeal muscle biopsies.15-18 
Due to infl ammati on, the compliance of the sphincter might be reduced, impeding the 
opening and thus the trans-sphincteric bolus fl ow.19 Ageing may be another cause of 
a diminished sphincter opening, but ageing does not seem to prolong the pharyngeal 
bolus transit ti me, neither does it disturb trans-sphincteric bolus fl ow coordinati on.20
Observed aspirati on was rare in our pati ents (n = 1). However, aspirati on-related 
signs were present in half the group. Two publicati ons revealed higher prevalences 
of aspirati on on VFS (24 and 61%) in infl ammatory myopathies. These studies also 
included polymyositi s and dermatomyositi s pati ents.8, 15 these studies, including the 
present study, used diff erent fl uid volumes for swallows. A diff erent fl uid consistency 
and volume, and a diff erent positi on of the head during VFS may have infl uenced these 
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prevalence figures. Differences in mechanisms of dysphagia within the inflammatory 
myopathies cannot be ruled out, either.
The sensitivity and specificity of questions regarding impaired propulsion were 
disappointing. However, for the detection of dysphagia through questions from the 
questionnaire the positive predictive value is the most important. The positive predic-
tive value appeared to be high enough to be of use when selecting patients to be 
investigated by VFS or for possible further treatment.
Despite the frequent occurrence of dysphagia in sporadic IBM only 54% of patients 
with dysphagia on the questionnaire had expressed swallowing difficulties to their 
physician spontaneously. This indicates that a proactive approach to detect dysphagia 
using a simple set of questions could facilitate early treatment and lead to prevention 
of complications.
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the purpose of this study was to explore the prevalence and nature of cardiac ab-
normalities in sporadic inclusion body myositis (IBM). Fifty-one sporadic IBM patients 
were cross-sectionally studied using history-taking, physical examination, measure-
ments of serum creatine kinase activity, the MB fraction (CK-MB), cardiac troponin T 
(cTnT) and I (cTnI), a 12-lead electrocardiogram (ECG) and 2-D echocardiography. Pres-
ent cardiac history was abnormal in 12 (24%) out of 51 patients, 12 (24 %) patients had 
abnormalities on ECG, mostly aspecific, and in 12 (24%) patients the echocardiograph 
showed abnormalities. Elevated CK-MB was present in 42 (82%) patients and 40 (78%) 
had an elevated ctnt in the absence of acute cardiac pathology. In contrast, in one 
patient (2%) cTnI was elevated. There was no apparent association between elevated 
biomarkers, ECG or echocardiographic abnormalities.
The prevalence of cardiac abnormalities in sporadic IBM does not seem to be higher 
than would be expected in these elderly patients. Elevated CK-MB and cTnT levels are 
common, in contrast to cTnI, but do not reflect cardiac pathology.
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Introducti on
Sporadic inclusion body myositi s (IBM) is a slowly progressive infl ammatory myopathy 
of striated skeletal muscle, parti cularly aff ecti ng the quadriceps muscles, forearm 
fl exors and pharyngeal muscles. Symptoms usually occur aft er the age of forty.1, 2
Muscle biopsy specimens show predominantly endomysial infl ammati on, with 
CD8+ T-cells invading non-necroti c muscle fi bres. These infi ltrates resemble those in 
polymyositi s (PM). Essenti al diff erences with PM are the presence of rimmed vacuoles 
and intracellular deposits of a host of proteins, including ß-amyloid and hyperphos-
phorylated tau in sporadic IBM.
Cardiovascular studies in PM and dermatomyositi s (DM), cross-secti onal or retro-
specti ve, reported abnormaliti es in 32.5-85% of the pati ents, comprising congesti ve 
heart failure, conducti on abnormaliti es, myocarditi s, arrythmias and cardiomyopa-
thy.3-6 At the ti me these studies were done, sporadic IBM was not yet considered a 
disti nct disease enti ty and the Bohan and Peter criteria then used, resulted in the 
inclusion of pati ents with sporadic IBM into the PM groups.7, 8 Cardiovascular case 
series in sporadic IBM have not been published as far as we know.
the present study explored the possible involvement of the heart in sporadic IBM 
pati ents using non-invasive techniques.
Methods
Study populati on
The study comprised 51 pati ents diagnosed with sporadic IBM, selected from a 
nati onal cohort of 86 IBM pati ents. The recruitment procedure has been previously 
described in detail.9 In short, a database of sporadic IBM pati ents was started through 
a nati onal survey in all large neurologic and rheumatologic centers in the Netherlands 
in order to identi fy as many sporadic IBM pati ents as possible. Clinical data and biopsy 
specimens of all pati ents previously coded with a diagnosis of sporadic IBM, a chronic 
or refractory myositi s or progressive myopathy of unknown origin, with an onset 
aft er the age of 45 years were reevaluated for sporadic IBM characteristi cs. Included 
pati ents fulfi lled the ENMC criteria for defi nite or probable sporadic IBM.10 the study 
protocol included a cross-secti onal clinical evaluati on, blood sample analysis, 12-lead 
electrocardiography (ECG) and transthoracic echocardiography. The studies were done 
at Leiden University Medical Centre aft er approval by the Ethics committ ee and att ain-
ing informed consent of all pati ents. From the remaining 35 pati ents who were not 
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included in the present study, 13 refrained from participation, 5 could not be located, 
6 died before starting the protocol (1 patient due to adenocarcinoma of the lung, one 
due to gastric bleeding, and 4 to causes unknown) and 11 did not undergo cardiac 
evaluation due to logistic difficulties.
Clinical evaluation
history-taking focussed on the presence of cardiovascular risk factors and previous 
history of ischemic heart disease, heart failure, cardiac arrhythmias and pericardial 
disease.
The physical examination comprised 12 automated blood pressure and pulse rate 
measurements taken within 30 minutes while seated, and a heart examination.
Blood sample analysis
Serum creatine kinase activity (sCK), the MB fraction (CK-MB) and cardiac Troponin T 
(cTnT) and Troponin I (cTnI) were analyzed. Normal values for sCK were ≤ 170 U/L in 
women and ≤ 200 U/L in men and for CK-MB ≤ 10 μg/L. The cut off value for cTnT was 
0.03 μg/L and for cTnI 0.2 μg/L.
Electrocardiography
The presence of any conduction disturbance, arrhythmia, myocardial ischemia or 
infarction was evaluated by ECG (25 mm/sec) as follows: heart rhythm was classified 
as sinus rhythm, atrial fibrillation or flutter, or paced rhythm. A QRS axis between -30° 
and -90° indicated a left axis deviation, an axis between +90° and +180° indicated 
right axis deviation.11 Complete bundle branch block (BBB) was defined by a QRS com-
plex duration of >120 ms. Extrasystolic beats, sinus bradycardia (<60 beats/min) and 
-tachycardia (>100 beats/min) were noted.
ST-segment depression >1mm and abnormal negative T-waves in 2 consecutive leads 
suggested myocardial ischemia. Pathological Q-waves in at least 2 consecutive leads, 
with a duration >0.04 s and a depth >25% of the R-wave voltage, indicated previous 
myocardial infarction.
Left ventricular (LV) hypertrophy was assessed using the Sokolow index.12 the cor-
rected QT-interval (QTc) was calculated according to Bazett’s formula.13
Echocardiography
Patients were imaged in the left lateral decubitus position using a commercially avail-
able system (Vingmed system Vivid-5; General Electric-Vingmed, Milwaukee, WI, USA). 
Standard 2-dimensional and color Doppler data, triggered to the QRS complex, were 
obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal (long- and 
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short-axis) and apical (2- and 4-chamber, long-axis) views. The images were stored 
for off -line analysis (EchoPac 6.0.1, General Electric Vingmed Ultrasound, Milwaukee, 
USA).
Both ECG and echocardiography were analyzed by one independent cardiologist 
blinded with regard to the clinical status of the pati ent, but aware of the diagnosis 
sporadic IBM.
LV dimensions and functi on were measured from M-mode images. LV wall moti on 
was classifi ed as abnormal when hypokinesia was observed. LV mass was calculated 
by the cube formula and using the correcti on formula proposed by Devereux et al.14 
LV mass index (LVMI) was calculated aft er correcti on for body surface area. A value of 
LVMI >110 g/m2 in women and >135 g/m2 in men defi ned LV hypertrophy.15
LV diastolic functi on was evaluated by the pulsed wave Doppler recordings of the 
transmitral infl ow velocity.16 Diastolic transmitral peak velociti es (E-wave and A-wave), 
the E/A rati o and the E-decelerati on ti me were measured. Valvular functi on was evalu-
ated with color Doppler echocardiography and standard conti nuous and pulsed wave 
Doppler examinati ons.
Stati sti cal analysis
Conti nuous variables were compared using the Mann-Whitney U-test. Categorical 
variables were compared using the Fisher exact test. Laboratory data are stated as 
median (range), other data are presented as mean ± standard deviati on.
Results
Study populati on and clinical evaluati on
All 51 sporadic IBM pati ents (67 ± 9 years, 34 men) completed the study protocol. Mean 
disease durati on was 11 ± 6 years. The investi gated group did not diff er signifi cantly 
from the original populati on group of 86 pati ents with regard to sex distributi on, age 
(at onset) and disease durati on.The cardiovascular history profi le up to inclusion is 
summarized in table 1 .
The majority of the pati ents (n = 39, 76%) reported no cardiovascular symptoms at 
the ti me of history taking. The remaining 12 pati ents (24%) disclosed exerti on-induced 
chest pain, dyspnea, nycturia or palpitati ons. None of the pati ents had had a myocar-
dial infarcti on within 3 months prior to evaluati on. The mean systolic and diastolic 
blood pressures at examinati on were 133 ± 19 and 77 ± 12 respecti vely. A cardiac 




Elevated sCK levels were observed in 42 (82%) patients, 506 U/L (64 – 3360) in men, 
246 U/L (44 – 802) in women. Elevated CK-MB levels were measured in 42 (82%) pa-
tients, 18 μg/L (2-124). Elevated cTnT levels were observed in 40 (78%) patients, (0.08 
µg/L (0.01 – 0.99)), and an elevated cTnI level of 0.22 µg/L was found in one patient. 
CK-MB was elevated in four patients with a normal sCK.
Electrocardiographic data
Most patients were in sinus rhythm (n = 47, 92%). Three (6%) patients had atrial fibril-
lation and 1 (2%) a paced rhythm. Mean heart rate was 69 ± 15 beats/min.




Diabetes Mellitus 1 (2%)





Myocardial infarction 8 (16%)
Coronary revascularisation 3 (6%)
Conduction abnormalities 5 (10%)
Requiring pacemaker 2 (4%)
Pericarditis 1 (2%)
heart failure 1 (2%)
Mitral valve abnormalities 2 (4%)






BMI = Body Mass Index, ACE-inhibitors = angiotensin converting enzyme inhibitors.
* Multiple items possible per patient
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The mean QRS durati on was 91 ± 20 ms. Thirty-four (67%) pati ents showed a normal 
QRS axis, two (4%) a right axis deviati on and 13 (25%) a left  axis deviati on. Two (4%) 
pati ents had complete BBB whereas 5 (10%) pati ents had incomplete BBB. Seven 
(14%) pati ents had signs of previous myocardial infarcti on whereas four (8%) had signs 
corresponding to our defi niti on of myocardial ischemia.
Nine (18%) pati ents had LV hypertrophy. Mean QTc durati on was normal.
Echocardiographic data
Most pati ents had a non-dilated LV with preserved functi on. Impaired systolic functi on 
(LV ejecti on fracti on <50%) was observed in 4(8%) pati ents. Fourteen (27%) pati ents 
met the echocardiographic criteria of LV hypertrophy. The LV diastolic functi on could 
be reliably assessed in 45 pati ents. The mean E/A rati o was 0.9 ± 0.6, which is in the 
normal range above the age of fi ft y.
The majority of the pati ents had normal valvular functi on. Mild mitral (n=7, 14%), 
aorti c (n=8, 16%), and tricuspid (n=7, 14%) regurgitati on were infrequently found and 
only 1 (2%) pati ent had moderate tricuspid regurgitati on.
Myocardial damage evaluati on by combining serum levels of cardiac 
biomarkers, ECG and echocardiographic fi ndings
To evaluate the clinical signifi cance of the raised biomarkers, we compared the 
values of biomarkers between pati ents with and without abnormaliti es on ECG and 
echocardiography. For this purpose, pathologic ECG (n=12, 24%) was defi ned by the 
presence of any conducti on abnormality, pathologic ST-segment depression or patho-
logic Q waves, whereas pathologic echocardiography (n=12, 24%) was defi ned by the 
presence of impaired systolic LV functi on or wall moti on abnormaliti es.
Of the pati ents with a normal ECG or echocardiography, 79% had raised CK-MB levels 
versus 100% in pati ents with a pathologic ECG or echocardiography (p = 0.2). For cTnT, 
these numbers were 79 and 85 % respecti vely (p = 0.8). CK-MB and cTnT levels did 
not diff er between the groups with and without pathologic ECG or echocardiography 
either ( p = 0.8 and 0.09, respecti vely).
The only pati ent with an elevated cTnI had pathologic fi ndings on ECG and echocar-
diography, including a wall moti on abnormality with an ejecti on fracti on of 18%.
Thus, raised cardiac biomarkers were not associated with pathologic fi ndings on ECG 
or echocardiography and furthermore, the majority of the pati ents with raised cardiac 




The present study showed that the vast majority of patients with sporadic IBM were 
asymptomatic with regard to cardiac symptoms at the time of investigation. The fre-
quencies of ECG and echocardiography abnormalities approximate those from large 
epidemiological studies in several cohorts from general populations with a similar 
age distribution as the present study.17-20 therefore, the prevalence and nature of the 
found abnormalities are considered to be unrelated to sporadic IBM. Consequently, 
standard cardiac evaluation in sporadic IBM is not considered mandatory. This is dif-
ferent from previous findings in PM and DM.
In the last decade, cardiac troponins (cTnT or cTnI) have emerged as more specific 
biomarkers of cardiac damage as compared to sCK or CK-MB, and particularly acute 
myocardial ischemia is based upon raised troponin levels.21, 22 Elevation of cTnT has 
been described in PM, DM and sporadic IBM patients without apparent cardiac isch-
emia.23, 24 In addition, one study and one case report describe normal cTnI levels in the 
presence of elevated cTnT in myositis.23, 25 In contrast to the present study, possible 
cardiac involvement was not studied by ECG, nor by echocardiography.
It has been hypothesized that CK-MB and cTnT, both expressed in fetal muscle, 
but down-regulated during development, are re-expressed in regenerating muscle 
fibers.24, 26, 27 These fibers are common in PM, DM and sporadic IBM muscle biopsies. 
Consequently, CK-MB and cTnT elevations arise in the absence of cardiac ischemia. 
Contrarily, ctnI, exclusively expressed in cardiac muscle, remains normal.28
In the present study, CK-MB and cTnT were commonly elevated in the absence of 
cardiac pathology. The only patient with an elevated cTnI had a severe cardiomyopa-
thy, explaining this elevation.29 these outcomes support the hypothesis that elevated 
CK-MB and cTnT levels in IBM are not of cardiac origin, but originate from skeletal 
muscle tissue.
the present study does not show evidence for cardiac involvement in sporadic IBM, 
and therefore we do not recommend routine comprehensive cardiac evaluation in 
patients with sporadic IBM without cardiac symptoms. Increased cardiac biomarkers, 
i.e., CK-MB and cTnT in sporadic IBM do not necessarily suggest cardiac damage. To 
detect cardiac ischemia in IBM patients cTnI is likely the most informative and recom-
mended biomarker.
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Chapter 5
Magnetic Resonance Imaging of 














To analyze whether magnetic resonance (MR) imaging of upper and lower extrem-
ity muscles in a large patient group with sporadic inclusion body myositis (IBM) is of 
additional value in the diagnostic work-up of sporadic IBM, 32 sporadic IBM patients 
were included in this study. MR parameters were evaluated in 68 muscles of upper and 
lower extremity including muscle atrophy, fatty infiltration and inflammation. These 
findings were correlated to disease duration, weakness and serum creatine kinase 
(sCK) levels. Fatty infiltration was far more common than inflammation. Muscles most 
frequently infiltrated with fat were the flexor digitorum profundus (FDP), anterior 
muscles of the upper leg and all muscles of the lower leg, preferentially the medial 
part of the gastrocnemius. The rectus femoris was relatively spared compared to other 
quadriceps muscles as well as the adductors of the upper leg.
Inflammation was common in general, but individually sparse, present in 78% of 
the patients with a median of 2 inflamed muscles per patient. A statistically significant 
correlation was found between the amount of fatty infiltration and disease severity, 
disease duration and sCK.
We provide a detailed description of the MR imaging in sporadic IBM and show a 
distinct pattern of muscle involvement. Relatively severe affliction of the medial com-
partment of the gastrocnemius, combined with relative sparing of the rectus femoris 
or involvement of the FDP can be indicative of sporadic IBM. MR imaging can contrib-
ute to the diagnosis in selected patients with clear clinical suspicion, but lacking the 
mandatory set of muscle biopsy features.
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Introducti on
Sporadic inclusion body myositi s (IBM) belongs to the idiopathic infl ammatory my-
opathies and is characterized by painless multi focal muscle weakness and wasti ng 
manifesti ng aft er the age of 40 years. Diagnosis is based upon the clinical features and 
characteristi c muscle biopsy fi ndings. Symptoms usually follow the onset of weakness 
in the quadriceps, fi nger fl exor or pharyngeal muscles. The spread of muscle weakness 
is errati c and asymmetric, but in general ventral muscle groups are more aff ected than 
dorsal muscle groups in the extremiti es, and girdle muscle groups are least aff ected.1 
The characteristi c features in the muscle biopsy are mononuclear infl ammati on with 
T-cell invasion of non-necroti c muscle fi bers, and rimmed vacuoles. In a subgroup of 
pati ents, histology does not show these characteristi c biopsy features initi ally, leading 
to a delayed or wrong diagnosis.2, 3
Magneti c Resonance (MR) imaging has become a useful modality in the evaluati on 
of infl ammatory myopathies.4 MR imaging provides detailed anatomic informati on 
and edema-like signal intensity changes give informati on on the acti vity of the disease, 
an advantage compared with other imaging modaliti es. Five previous studies describe 
MR imaging in pati ents with sporadic IBM. However, in contrast to our study, those 
studies comprise much smaller pati ent groups and were restricted with regard to the 
number of muscles studied.5-9 It has been stated that MR imaging could disti nguish 
polymyositi s (PM) from sporadic IBM by the presence of isolated muscle infl am-
mati on in the absence of fatt y infi ltrati on or atrophy, as opposed to the fi ndings in 
sporadic IBM.6 Another study focused on the forearm muscles, and showed explicit 
fatt y changes in the fl exor digitorum profundus muscle, someti mes preceding clinically 
detectable weakness in this muscle.9
To give an elaborate view on the severity and distributi on of abnormaliti es in MR 
imaging, we investi gated a large and well-defi ned group of sporadic IBM pati ents. We 
investi gated whether MR imaging could be of additi onal value to the clinical features 
during the diagnosti c process.
Pati ents and Methods
Pati ents
The study comprised 32 pati ents diagnosed with sporadic IBM. All pati ents fulfi lled the 
ENMC criteria10 for defi nite (n=31) or probable (n=1) sporadic IBM. Pati ents were ran-
domly selected from the Leiden University Medical Center (LUMC) registry of sporadic 
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IBM patients. The study was approved by the Ethics committee of the LUMC and all 
patients gave informed consent.
History taking included functional grading scales (Barthel index, scale 0-20, River-
mead mobility index, scale 0-15 and Brooke’s grading system, scale 3-23 [with 23 being 
the worst score]). Physical examination comprised manual muscle strength testing 
(MMT) of 34 muscle groups using the six-point British Medical Research Council (MRC) 
scale.
Serum creatine kinase activity (sCK) was measured (normal value ≤ 170 U/L in 
women and ≤ 200 U/L in men).
MR imaging
MR imaging examinations were performed at 1.5T (Gyroscan NT15; Philips Medical 
System, Best, The Netherlands) by the following standard protocol. Each series was 
obtained with a body coil with the patient supine. The following sequences were used: 
(a) axial T1-weighted spin-echo series with 600/20 (repetition time msec/echo time 
msec), section thickness of 6.0 mm, field of view 250 mm, rectangular field of view of 
59%, NSA=2 and an acquisition matrix of 205 x 256. (b) axial STIR series with 1400/15 
(repetition time msec/echo time msec), section thickness of 6.0 mm, field of view 250 
mm, rectangular field of view of 59%, NSA=4 and an acquisition matrix of 202 x 256. 
Imaging was performed of the right shoulder, upper and lower right arm, the pelvis, 
and both upper and lower legs. Two musculoskeletal radiologists, with respectively 
4 and 14 years of clinical experience, without knowledge of the clinical findings, but 
aware of the diagnosis sporadic IBM, evaluated all MR examinations in consensus. 
Muscles were scored for muscle atrophy, fatty infiltration and edema-like changes. 
Muscle atrophy was defined as evident loss of muscle volume, scored as present or 
absent. T1-weighted MR images were used to estimate the degree of fatty infiltra-
tion. Abnormal signal intensity was consequently classified as mildly abnormal if only 
fatty streaks of increased signal intensity could be observed (<30% of fat compared 
to muscle), moderately abnormal if 30-60% of the muscle showed increased signal 
intensity and severely abnormal if at least 60% of the muscle showed an increased 
signal intensity.11
On StIR images any level of high signal intensity of the muscles was considered an 
abnormal finding: edema-like changes. In this population this is considered inflam-
mation as previously used.4, 6, 8, 12, 13 this was scored as present or absent. Asymmetry 
could be scored in the lower extremities only, as both sides were visualized.
the examined muscles were:
i) shoulder region: deltoid, infraspinatus, supraspinatus, subscapularis; ii) upper 
arm: biceps, triceps; iii) forearm: flexor carpi ulnaris, flexor carpi radialis, flexor 
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digitorum profundus (FDP) and superfi cialis (FDS), brachioradialis, extensor carpi ul-
naris and radialis, extensor digitorum communis, supinator, pronator teres; iv) pelvis: 
gluteus minimus, gluteus medius, gluteus maximus, iliopsoas, obturatorius internus 
and externus, pecti neus; v) upper leg: quadriceps femoris (rectus femoris, vastus late-
ralis, medialis and intermedius), semimembranosus, semitendinosus, biceps femoris, 
sartorius, gracilis, adductor brevis, longus and magnus; vi) lower leg: gastrocnemius 
(lateral and medial part), soleus, ti bialis posterior, ti bialis anterior, peroneus longus, 
and extensor digitorum longus. In total, 68 separate muscles were evaluated.
Stati sti cs
Descripti ve measures are presented as mean ± standard deviati on, unless otherwise 
stated. Correlati on between MR imaging and diff erent clinical parameters were cal-
culated using the Spearman rank test. the Mann-Whitney U-test was performed to 
compare total strength of pati ents with and without a fatt y infi ltrated FDP. A p-value 
of < 0.05 was considered to be signifi cant.
Results
History, clinical examinati on and serum creati ne kinase (sCK)
Mean age of the 32 included pati ents (19 men) was 68 ± 9 years, with a mean disease 
durati on of 12 ± 5 years. Mean ti me to diagnosis was 8 ± 5 years. Median Barthel index 
score (range) was 19 (6-20), Rivermead mobility index score 12 (0-15) and for Brooke’s 
grading system 6 (3-16).
With MMT, the most frequent aff ected muscles were the ventrally located muscles 
in the arm, the upper and the lower leg. The most frequent and severely (MRC-scale 
0-3) aff ected muscles were the FDP (n=15, 47%) and quadriceps (n=11, 34%). Rela-
ti vely spared muscles were the infraspinatus and adductors of the upper leg, which 
had normal strength in 19 (59%) and 21 (66%) pati ents respecti vely.
sCK was elevated in 28 pati ents (88%). Median sCK was 739 (121-3360) for men and 
265 (44-802) for women.
MR imaging
General fi ndings:
In two pati ents, the quality of MR imaging of the forearm was not suffi  cient to be 
evaluated due to moti on arti facts. In all pati ents MR images showed abnormaliti es.
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All patients had fatty infiltrated muscles. The median number of muscles infiltrated 
by fat per patient was 40 (range 5-68, interquartile range 29)
With regard to the extent of involvement, the leg muscles were more frequently 
and severely affected as compared to the arm muscles. The lower legs were more 
frequently and severely affected than the upper legs. The shoulder and pelvic girdle 
muscles and adductors of the upper leg were relatively spared (table 1).
Inflamed muscles were present in 78% of the patients. The median number of in-
flamed muscles was 2 (range 0-20, interquartile range 4). The most frequent inflamed 
muscles were the deltoid muscle (16%), the extensor carpi ulnaris (20%), the medial 
(22%) and lateral part of the gastrocnemius (16%) and the soleus muscle (16%). Isolated 
muscle inflammation (i.e. without fatty infiltration) was observed in 13 of all observed 
muscles. This phenomenon was mostly seen in muscles which were relatively spared 
from fatty infiltration, such as the thigh adductors (n = 5) and in the extensor carpi 
ulnaris (n = 2) (Figure 6C and 6D).
Atrophy was present in 94% of the patients. The median number of atrophic muscles 
was 22 (range 0-68, interquartile range 28). The most frequent atrophic muscles were 
the FDP (60%), the vastus muscles (69%) and the medial head of the gastrocnemius 
(81%). No hypertrophy was found.
Asymmetry of abnormalities (fatty infiltration as well as inflammation) was pres-
ent in 14 patients (44%) in the lower extremities. Asymmetry of fatty infiltration was 
mostly seen in the adductor magnus and the tibialis anterior muscle (13% in both), 
Table 1. Mean frequency of fatty infiltrated muscles and of those with severe fatty infiltration in 
different extremities








Anterior part 84 50
Posterior part 58 26
Lower 87 44
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whereas asymmetry of infl ammati on was mostly seen in the ti bialis posterior and 
soleus muscle (9% in both).
MR imaging fi ndings per body region:
Shoulder (Figure 1-3):
Involvement through fatt y infi ltrati on of shoulder muscles as a group was less 
frequent and severe than in other upper extremity muscles groups (table 1). Fatt y 
infi ltrati on in the shoulder region was most frequently observed in the subscapular 
muscle (n=18, 56%). Infl ammati on was most frequent in the deltoid muscle; fi ve (16%) 
pati ents had infl ammatory changes in the deltoid muscle compared with one (3%) 



























































































































































































































































































































































Upper arm (Figure 1-4):
Fatty infiltration was equally present in the biceps and triceps. No inflammation was 
seen in the biceps. Only two patients had inflammatory changes of the triceps.
Forearm (Figure 1-4, 5A, 5B, 6B,6C and 6D):
The most frequently and severely affected muscle of the upper extremity by fatty in-
filtration was the FDP. Twenty-two (73%) patients had an FDP infiltrated with fat, in 13 
patients (43%) affliction was considered as severe. Atrophy was also most frequently 
observed in the FDP (n=18, 60%). In 8 patients (27%), the FDP was unaffected.
As a rule, if the FDP did not show fatty infiltration, then it was absent in all forearm 
muscles. The only exception was a patient with some fatty streaks in the supinator 
muscle. Preference for fatty infiltration was also seen in the FDS and the supinator 
muscle, but they were clearly less severely affected than the FDP.
Patients with an unaffected FDP on MR imaging had a mean disease duration of 13 























































































































































































































































































































































Figure 2. Frequency of inflammation of muscle groups for the total group of patients.
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Infl ammatory changes were most frequently seen in the extensor carpi ulnaris (n=6, 
20%).
Pelvis (Figure 1-3):
The muscles around the pelvis were less frequently and severely aff ected by fatt y 
infi ltrati on than other muscle groups of the lower extremity (table 1). The gluteus 
maximus was the most frequently aff ected muscle by fatt y infi ltrati on (n=19, 59%) of 
the gluteal musculature, although not severely (9%) and without asymmetry. None of 
the gluteal muscles had infl ammatory changes.
Upper leg (Figure 1-4, 5C and 5D):
The anterior muscle group of the upper leg was frequently aff ected by fatt y infi ltra-
ti on. The rectus femoris was relati vely spared compared to other quadriceps muscles, 
but normal in only 7 pati ents (22%). Complete sparing of the quadriceps muscles was 
seen in only two cases. In these pati ents, all other anterior and posterior thigh muscles 
Figure 3. Frequency of atrophy of muscle groups for the total group of pati ents.
ChAPtER 5
68
were spared as well, but both patients had abnormalities in the lower legs. No patient 
had exclusive involvement of quadriceps.
The posterior muscle group of the upper leg was far less frequently and less severely 
affected by fatty infiltration as compared to the anterior compartment (table 1). The 
hamstring muscles more often had a preference for fatty infiltration as compared to 
the relatively spared adductor muscles.
Figure 4. Frequency of muscles in the different extremities being infiltrated with fat by > 30%.
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Infl ammati on was rare, the most frequently infl amed muscle was the adductor 
brevis (n = 4, 13%).
Atrophy was common in all muscles of the anterior compartment of the upper leg 
with excepti on of the gracilis muscle. This muscle was regarded atrophic in only 28% 
of the pati ent group.
Figure 5. T1-weighted images with diff erent levels of fatt y infi ltrati on in the forearm and legs
Right forearm showing moderate (A) and severe (B) fatt y infi ltrati on of the FDP.
Upper legs (C and D) showing severe fatt y infi ltrati on of the vastus muscles, with relati ve sparing 
of the rectus femoris muscle and hamstrings.
Lower legs showing moderate (E) and severe (F) fatt y infi ltrati on of the gastrocnemius muscles, 
especially the medial part. Image F shows relati ve sparing of the extensor digitorum longus, ti bialis 
posterior and soleus muscles.
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Lower leg (Figure 1-4, 5E, 5F and 6A):
All muscles of the lower leg were commonly affected by fatty infiltration, the medial 
part of the gastrocnemius muscle appearing as the most severely affected one.
Inflammatory changes in the lower extremity were also more common in the lower 
leg, again with a preference for the medial part of the gastrocnemius, showing inflam-
mation in 7 patients (22%). Atrophy was common in all lower leg muscle groups with 
the exception of the soleus and the tibialis posterior muscles; these muscles were 
atrophic in respectively 11 (34%) and 10 (31%) patients only.
Correlation between MR imaging and other findings
There was a statistically significant correlation between disease duration and number 
of muscles infiltrated by fat (r= 0.6, p= 0.001). However, the pattern of muscles invaded 
with fat in patients with short and long disease duration was similar. No correlation 
was found between disease duration and the number of inflamed muscles (r= 0.4, p= 
0.8), implying that short disease duration was not a prerequisite for inflammation. In 
Figure 6. Images of inflammation (STIR) of the forearm and legs
Lower legs (A) showing inflammation in the medial part of the gastrocnemius muscle.
Right forearm (B) showing inflammation in the extensor carpi ulnaris muscle (ECU).
Right forearm forearm (C, T1-weighted) showing extensive fatty infiltration of all muscles, with 
sparing of the ECU. A STIR image (D) of the same patient shows exclusive inflammation of the ECU.
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fact, the three pati ents with the highest frequency of infl amed muscles (> 11) had a 
disease durati on of 10, 11 and 16 years. No correlati on was found between age and 
MR imaging abnormaliti es. The seriousness of functi onal incapacity, as measured by 
the grading scales, was associated with the number of muscles infi ltrated with fat. 
(Barthel r= -0.646, p< 0.005, Rivermead r= -0.743, p< 0.005, Brooke r= 0.628, p< 0.005). 
Functi onal grading scales did not correlate with the number of infl amed muscles.
Weakness was associated with more fatt y infi ltrati on as the sum score of all muscles, 
tested with MMT, had a negati ve correlati on with the number of muscles infi ltrated 
by fat (r= -0.8, p< 0.005). The number of infl amed muscles showed no correlati on with 
the MMT sum score (r= -0.2, p= 0.4).
Pati ents with an FDP infi ltrated with fat, scored signifi cantly worse on MMT sum 
score (median = 245, n = 22) than pati ents with a normal FDP on imaging (median = 
286, n = 8) ( p = 0.002).
FDP muscles of normal strength with MMT, present in 5 pati ents, were normal on 
MR imaging, except for one case with some fatt y streaks.
sCK levels showed a moderate, although negati ve correlati on with the number of 
fatt y infi ltrated muscles on MR imaging (r= -0.417, p= 0.017), but did not correlate with 
the number of infl amed muscles (r = 0.252, p= 0.16).
Discussion
MR imaging is an easy and excellent technique to visualize muscle pathology in spo-
radic IBM, as demonstrated by the results of this large cohort of pati ents. All sporadic 
IBM pati ents showed abnormaliti es on MR imaging of their muscles. Fatt y infi ltrati on 
was the most common abnormality in all pati ents. It was observed, in decreasing order 
of frequency, in the lower legs, then the upper legs, followed by the forearm, pelvis, 
upper arm, and the shoulder girdle. However, within these body parts large diff er-
ences were seen. In the upper legs the adductors were most frequently spared, the 
hamstrings intermediately aff ected, and the quadriceps most aff ected. In the forearm, 
there proved to be preferenti al affl  icti on of the FDP muscle, someti mes as single 
muscle involvement.
Overall, in MR imaging, ventrally located muscles were more frequently and severely 
aff ected than dorsally located muscles, and abductors and adductors of the pelvic and 
shoulder girdle were the most spared, confi rming the clinical fi ndings.1
MR imaging also provides informati on on muscles that cannot be tested clinically. 
For example, in the lower leg the plantar fl exors of the foot, the gastrocnemius and 
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soleus muscles, are clinically relatively spared; however, MR imaging points out that 
especially the medial head of the gastrocnemius is abnormal, with relative sparing of 
the soleus muscle. In the upper leg, the rectus femoris is relatively spared compared 
to the other quadriceps muscles.
Involvement of the FDP appeared not to be obligatory for the disease. Although 
Sekul et al9 found a very high incidence of fatty infiltration in the FDP in 20/21 sporadic 
IBM patients with an average disease duration of 6.5 years, we found unaffected FDP 
muscles in a quarter of sporadic IBM patients. In one patient, MR abnormalities in the 
FDP preceded clinical detectable weakness, which has been described earlier.9
Edema-like changes are not specific for inflammatory myopathies, but can also 
be seen in other neuromuscular disorders (NMDs), e.g. in muscular dystrophy.11. As 
in muscular dystrophy, sporadic IBM patients also showed that muscles affected by 
edema-like changes showed less fatty infiltration. As edema-like changes were not 
associated with disease duration, in contrast to fatty infiltration, these findings hint 
towards inflammation preceding fatty infiltration.
The pattern of fatty infiltration is the most informative when one wants to discrimi-
nate between different NMDs. The sporadic IBM pattern described here is distinct 
from other myopathies that are to be considered in an elderly patient with insidious 
onset of muscle weakness, including dystrophinopathies, polymyositis (PM) and der-
matomyositis (DM).
In dystrophinopathies (Becker muscular dystrophy and limb-girdle muscle dys-
trophies), the quadriceps muscles are also commonly invaded with fat. The biceps 
femoris, the semimembranosus and the adductors of the upper leg are also preferably 
affected in these disorders, in contrast to sporadic IBM.14 In PM, fatty infiltration is far 
less pronounced than in sporadic IBM. Another difference is the pronounced localiza-
tion of fat in the anterior muscle groups of the upper and the lower leg in sporadic IBM 
contrary to PM.6
In DM, inflammation is more pronounced than fatty infiltration and edema is found 
along the fascia and subcutaneous fat.15 PM and DM have more symmetrical abnor-
malities in contrast to sporadic IBM. The marked abnormalities of the FDP as observed 
in sporadic IBM have never been described in another myopathy.
In clinical practice, selective MR imaging is preferred above imaging of 6 different 
body regions, mainly because imaging is time consuming. To differentiate between 
the myopathies mentioned above we suspect imaging of the upper legs and forearm 
to be the most informative. The sporadic IBM pattern of the upper leg (relative spar-
ing of the rectus femoris, hamstrings and adductor muscles) and the extend of fatty 
infiltration (87%), as well as the asymmetry, mostly seen in the adductor magnus, can 
effectively differentiate sporadic IBM from other myopathies.
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Although there is a high frequency of FDP abnormaliti es in sporadic IBM on imaging, 
subclinical involvement appeared rare. Imaging of the forearm can be used to confi rm 
weakness of the FDP, especially when the presence of weakness is subtle or uncertain.
The absence of a control group limits the interpretati on of the study. Discrimina-
ti on from other myopathies was therefore not based on direct comparison, rather on 
knowledge from published arti cles describing MR fi ndings in other myopathies. The 
awareness of the diagnosis may also raise concern about bias by the radiologists .
Although the pati ents in this study had a relati vely long mean disease durati on, 
subgroups of pati ents with a shorter and longer disease durati on had a similar patt ern 
of fatt y infi ltrati on.
In summary, although muscle involvement on MR imaging in individual sporadic IBM 
pati ents is diverse, it shows a patt ern in sporadic IBM, diff erent from other myopathies. 
The diagnosis of sporadic IBM is oft en made aft er a mean disease durati on of 7 years 
due to a combinati on of pati ent and doctor’s delay.16 Not uncommonly the diagnosis 
is diffi  cult to establish because of a not yet typical clinical picture or repeated muscle 
biopsies not showing the mandatory features. MR imaging of the skeletal muscles can, 
especially in these cases, contribute to a diagnosis of sporadic IBM.
Key messages
1. Fatt y infi ltrati on is the most common MR abnormality in sporadic IBM and cor-
relates with weakness
2. The patt ern of distributi on of fatt y infi ltrati on in sporadic IBM muscle is thought to 
be specifi c for the disease
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Sporadic inclusion body myositis (IBM) is the most frequent acquired myopathy above 
the age of fifty. The exact mechanism causing this disease is not known, but immune-
mediated features are prominent and are probably to play a role in its pathogenesis. 
TREX1 gene mutations are associated with a large range of auto-immune diseases, 
such as systemic lupus erythematosus. We investigated whether mutations in the 
TREX1 gene were associated with sporadic IBM. Fifty-four patients with sporadic IBM 
were tested for TREX1 mutations by direct sequencing. All 54 patients tested negative 
for pathogenic mutations in the TREX1 gene. One presumed non-pathogenic polymor-
phism was found in 42 out of 54 patients. We conclude that TREX1 mutations do not 
play a role in the pathogenesis of sporadic IBM.
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Introducti on
Sporadic inclusion body myositi s (IBM) is an acquired myopathy presenti ng mostly 
above the age of fi ft y. Pati ents usually present with painless weakness of the quadri-
ceps muscles, fi nger fl exors or with dysphagia. Hallmarks of sporadic IBM are changes 
in the muscle with an infl ammatory as well as degenerati ve character. A cause-eff ect 
relati onship between these features is at present lacking and the pathogenesis 
is unclear. One theory supporti ng the idea that sporadic IBM is primarily immune-
mediated, is based on the initi ati on of an immune response by an unknown cause 
leading to clonal expansion of CD8+ T-cells and invasion of non-necroti c muscle fi bers 
and cytokine release. In this view, the degenerati ve muscle fi ber changes are second-
ary.1 The strong associati on with the autoimmune-prone 5.1 HLA haplotype and high 
incidence of other autoimmune diseases in pati ents with sporadic IBM support an 
autoimmune pathogenesis. However, the degenerati ve muscle changes and lack of 
eff ect of immune modulati ng therapies in sporadic IBM are diff erent from many other 
immune-mediated disorders.
We hypothesized that TREX1 might play a role in sporadic IBM. Mutati ons in the 
TREX1 gene are linked to a spectrum of autoimmune diseases, i.e. Aicardi-Gouti ère, 
childblain lupus and systemic lupus erythematosus.2 Futhermore, trex1 knockout mice 
were reported to spontaneously develop an infl ammatory myocarditi s.3 tREX1 is the 
major 3’-5’ exonuclease in mammalian cells and acts preferenti ally on single-stranded 
DNA (ssDNA). It is localized in the cytoplasm but can be mobilized to the nucleus in 
case of DNA damage. A study in mouse embryo fi broblasts with a Trex1 -/- phenotype 
showed that Trex1 defi ciency lead to a consti tuti ve acti vati on of DNA damage check-
point and extranuclear accumulati on of endogenous ssDNA.4 these changes may lead 
to autoimmunity, but the exact mechanism of acti on has not yet been clarifi ed. TREX1 
defi ciency and the consequent accumulati on of ssDNA in the cytoplasmic compart-
ment are thought to trigger an anti viral-like immune response through acti vati on of 
the innate immune response. In sporadic IBM abnormal expression of an unidenti fi ed 
ssDNA binding protein in skeletal muscle fi bers has been demonstrated,5 as well as 
accumulati on of TAR DNA binding protein-43 (TDP-43).6 ssDNA accumulati on could 
trigger the acti vati on of the innate immune response in sporadic IBM pati ents. Accu-
mulati on of ssDNA results in elevated levels of type I interferons in the absence of an 
infecti on.4, 7 tREX1 has also been opted to be a negati ve sti mulator of the interferon-
sti mulatory DNA response, which causes increased immune acti vity.8 Alternati vely, 
TREX1 defi ciency leads to acti vati on of NK and T-cells, thus causing infl ammati on,7, 9 
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which may be related to the T-cell invasion of non-necrotic muscle fibers in sporadic 
IBM.
In this study we explored whether TREX1 mutations are associated with sporadic 
IBM.
Methods
The present study comprised 54 patients diagnosed with sporadic IBM, selected from 
a national cohort of 86 patients with sporadic IBM. All patients gave informed consent. 
The study was approved by the Ethics committee of the Leiden University Medical 
Center. All patients fulfilled the ENMC criteria10 for definite (n=49) or probable (n=5) 
sporadic IBM. the TREX1 gene was screened for mutations by direct sequencing. The 
coding exon with the surrounding intronic regions was divided in three fragments 
and amplified by PCR. The primers used were: TREX1_Ex2AF5’gaatgtgctggtcccactaa
gg3’, TREX1_Ex2AR 5’aaggctaggagcaggttggc3’, TREX1_Ex2BF 5’ctctccctgtgtgtggctcc3’, 
TREX1_Ex2BR 5’ttgtgacagcagatggtcttgg3’, TREX1_Ex2CF 5’ctaggcagcatctacactcgcc3’, 
TREX1_Ex2CR 5’atcctgctagggaaagtgaggg3’. PCR products were analysed on an ABI3730 
sequencer (Applied Biosystems, Foster City, CA, USA) and genotypes were assigned 
using SeqScape software (Applied Biosystems). The reference sequence NM_016381 
(TREX1 isoform A) was used and sequence variants were described according to the 
HGVS nomenclature recommendations.
Results
The patients were 50-87 years of age (median 69) and 69% were male. The duration 
of symptoms varied between one and 29 years (median 11). Thirty-two patients (59%) 
presented with weakness of the quadriceps, 9 patients (17%) with finger flexor weak-
ness and 6 (11%) with dysphagia. All muscle biopies showed endomysial lymphocytic 
infiltrates, invasion of non-necrotic muscle fibers and rimmed vacuoles. Nineteen pa-
tients (35%) had another auto-immune disease, such as rheumatoid arthritis, type I 
diabetes or sarcoidosis.
All 54 patients tested negative for pathogenic mutations in the TREX1 gene. We did 
detect one single polymorphism (c.696C>T p.Tyr232Tyr) in 42 of the 54 patients. This 
polymorphism is frequently found in the Caucasian population and is considered to be 
non-pathogenic.
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Discussion
The results of this geneti c screening of well-defi ned sporadic IBM pati ents did not 
reveal a role for TREX1 mutati ons in sporadic IBM. This does not rule out a TREX1 
mutati on in a rare case of sporadic IBM, but given the relati vely large group of pati ents 
an important pathological role of TREX1 can be considered very unlikely. Whether 
TREX1 accumulates in the sporadic IBM muscle as a secondary eff ect and therefore 
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Sporadic IBM is a rare disease, but it is the most common among the myopathies with 
onset aft er the age of fi ft y. Men are more frequently aff ected than women. Symptoms 
most frequently start with weakness in the quadriceps muscles, the fi nger fl exors or 
pharyngeal muscles, the latt er resulti ng in swallowing dysfuncti on. Diagnosti c pitf alls 
sti ll contribute to a delay in diagnosis. The pathogenesis of sporadic IBM remains an 
enigma, with uncertainti es as to whether a degenerati ve or an infl ammatory pathway 
causes the disease.
At the start of our studies long term follow-up data were lacking. In the second chap-
ter of this thesis the results of such a follow-up study in 64 sporadic IBM pati ents 
have been described. The aim was to investi gate the rate and distributi on of weakness 
progression over years and the nature of disabiliti es that develop during the course 
of the disease. Furthermore, life expectancy and causes of death in sporadic IBM 
pati ents were described. Pati ent characteristi cs related to the course of the disease 
were sought for.
As expected, the course of the disease was progressive, with a mean decline on 
manual muscle testi ng of 3.5% per year, and 28.8% over a ten-year period. For quan-
ti tati ve muscle testi ng, these numbers are somewhat higher, 5.4% and 39.4% percent 
respecti vely. We cannot be sure regarding the linearity of the decline, as we examined 
pati ents at two ti me points only. However, almost all pati ents reported their weakness 
being relentlessly progressive during the course of the disease. Furthermore, a sub-
group of pati ents was indeed examined 50 weeks aft er baseline as they parti cipated 
in another study. The degree of decline in strength in these pati ents aft er 50 weeks 
was comparable with our calculated rates. Another recent study describing the rate 
of muscle decline tested by quanti tati ve muscle testi ng in 66 sporadic IBM pati ents 
reports a strength decline of 0.79% per month.1 the calculated rate of decline per year 
would be 9.1%, which seems much higher than the rate we found in our pati ent group 
(5.4%). In their study, 4 muscles were tested (biceps, triceps, iliopsoas and quadriceps 
femoris), in contrast to 14 muscle groups in our study. If we restrict our study to these 
four muscles, the calculated rate of decline would be 9.4% per year, comparable with 
Lindberg’s fi ndings. Recently, Cortese et al. found a 5.2% decline on manual muscle 
testi ng (23 muscle groups) aft er one year in 23 subjects.2 No prognosti c value could 
be att ributed to a single clinical feature, similar to the fi ndings of Lindberg et al. and 
Cortese et al.1, 2 Muscle strength in the lower legs declined most rapidly, followed by 
that of the forearms and upper legs. In our study the more severe affl  icti on of ventral 
muscles as compared to the dorsal ones in the early stage of the disease eventually 
disappeared in the lower legs. The severity of the ongoing strength loss is refl ected 
in the functi onal grading scale scores, which showed that 40% of pati ents could be 
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considered to be completely or severely dependent 20 years after onset. The mean 
time between the first symptom and the first use of a wheelchair was 16 years in our 
study, as has been confirmed by two other studies.2, 3 The assumption that the mild 
course and slow decline of muscle strength in sporadic IBM does not result in major 
disabilities is refuted by the findings in our study and is confirmed in a later study of 
Cortese et al, who also concluded sporadic IBM to be a disabling disease.2
Life expectancy was normal in our patient group, and this is supported by two other 
recently published papers.1, 3 however, in this chapter we described causes of death in 
the sporadic IBM population to be significantly different from an age-matched general 
Dutch population. Patients died more often due to disorders of the respiratory system, 
in particular (aspiration) pneumonia. This is possibly a reflection of weakness of respi-
ratory and pharyngeal muscles. Inamori et al. performed an autopsy in a sporadic IBM 
patient and reported inflammatory changes as well as rimmed vacuoles in the dia-
phragm.4 together with possible involvement of the abdominal muscles, impairment 
of respiration, coughing and swallowing may result in aspiration and pneumonia. A 
higher rate of aspiration pneumonia in sporadic IBM has been described before.5 In this 
study 19 patients were followed during approximately 50 months. Thirteen patients 
died during follow-up, eight out of these due to aspiration pneumonia. In the other 
cases, the causes of death were unknown. Cachexia was also seen more frequently in 
our sporadic IBM patient group, supposedly reflecting the great impact that muscle 
wasting and dysphagia can have on these patients at end-stage disease. Furthermore, 
an unexpectedly high number of patients asked for end-of-life care interventions, 
including euthanasia (6.5%) and continuous deep sedation (6.5%), approximating the 
rates in amyotrophic lateral sclerosis in the Netherlands.6 this underlines the high 
disease burden in the final stage of sporadic IBM.
The effect of use of the immunosuppressant drug methotrexate for 48 weeks on 
weakness progression in our patient group in a previous study was negligible. Ben-
vensite et al.3 confirmed that immunosuppressants do not slow down weakness 
progression. They performed a long-term observational study with 136 sporadic IBM 
patients. Seventy-one of these patients had received immunosuppressive treatment 
(most frequently prednisone) for a median time of 41 weeks. At their last visit, patients 
who had received immunosuppressants were even more severely affected according 
to several disability scales as compared to patients who did not have used immuno-
therapy. Contrarily, Lindberg et al1 conclude that sporadic IBM patients treated with 
different kinds of immunosuppressive drugs have a smaller decline of muscle strength 
of the biceps muscle only. However, this conclusion is based on retrospective and 
un-blinded data collection. Furthermore, weakness progression of the quadriceps 




our study. In additi on, their conclusion is based on treatment with a combinati on of 
immunosupressants. The authors also menti on that two pati ents in their study group 
died due to complicati ons related to immunosuppressive drug use. Therefore, as long 
as a clear benefi t of immunosuppressive drugs has not been shown in a properly 
conducted clinical trial, their role should be considered with great cauti on in the treat-
ment of sporadic IBM.
Our study revealed the high impact of the ongoing progression of weakness on 
pati ents. While sporadic IBM pati ents remain ambulant and independent in the initi al 
stage of the disease, the end-stage is characterized by serious disability. their normal 
life expectancy goes along with a prolonged disease burden, with disabiliti es and 
handicaps having a serious impact on the life of these pati ents.
In the third chapter the frequency and nature of swallowing dysfuncti on and the way 
in which dysphagia can be detected best have been described. Fift y-seven pati ents 
were interviewed using a questi onnaire for dysphagia and 43 of these pati ents un-
derwent swallowing video fl uoroscopy (VFS). We aimed to describe the frequency 
and symptoms of dysphagia in sporadic IBM pati ents and to identi fy questi ons from 
a questi onnaire predicti ng swallowing abnormaliti es on VFS. Furthermore, we tried 
to determine the mechanism of dysphagia in these pati ents. Sixty-fi ve percent of 57 
pati ents had symptoms of dysphagia. Remarkably, only a small proporti on of pati ents 
had ever menti oned their swallowing dysfuncti on to their physician. Two questi ons 
from a structured questi onnaire were identi fi ed to adequately predict abnormaliti es 
on VFS. These questi ons were: ‘Do you have to swallow repeatedly in order to get rid 
of food’ and ‘Does food get stuck in your throat’.
The nature of dysphagia was studied using VFS. We found abnormaliti es on VFS in 
79% of 43 pati ents. Most abnormaliti es were signs related to impaired propulsion of 
the bolus, such as cricopharyngeal dysfuncti on. Aspirati on-related signs were found in 
almost half of the pati ents, but actual aspirati on was rarely observed. Cricopharyngeal 
dysfuncti on was a frequent abnormality, as described in another study investi gati ng 
dysphagia in sporadic IBM.5 Murata et al7 investi gated 10 sporadic IBM pati ents with and 
without dysphagia. they performed VFS and computed pharyngoesophageal manom-
etry. All pati ents, including the pati ents without dysphagia, showed cricopharyngeal 
dysfuncti on. Additi onally, the computed pharyngoesophageal manometry revealed a 
lack of oropharyngeal peristalti c acti vity in all pati ents, with an absence of degluti ti ve 
relaxati on of the upper esophageal sphincter in pati ents with dysphagia. Based on cur-
rent knowledge dysphagia in sporadic IBM is most likely caused by pharyngeal muscle 
weakness, with the inability to generate suffi  cient intrabolus pressure to establish re-
laxati on of the cricopharyngeal muscle. This poor synchrony between the contracti ng 
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pharynx and the relaxing sphincter causes stasis of the bolus in the pharynx. treatment 
of swallowing dysfunction can be invasive or non-invasive. Invasive interventions in-
clude cricopharyngeal myotomy, being the most frequently applied therapy, followed 
by pharyngoesophageal dilatations. Cricopharyngeal myotomy seems to benefit 63% 
of patients with sporadic IBM, whereas pharyngoesophageal dilatation is reported to 
be less effective (33%).5 the reason for treatment failure could be due to a too far 
advanced pharyngeal weakness. It has been established that prolonged obstruction 
at the pharyngoesophagal outlet leads to pharyngeal weakness.8 therefore, it seems 
plausible to treat patients before dysfunction is too severe in order to have the optimal 
result. Treatment effect can possibly be predicted by measurements of the intrabolus 
pressures, a measurement of pharyngeal strength, but studies investigating this are 
lacking so far. Another invasive treatment for dysphagia is botulin toxin injections in 
the cricopharyngeal sphincter, but studies investigating the benefit are lacking. There 
are some case reports9, 10 reporting a positive effect on swallowing function following 
IvIg therapy. Furthermore, one placebo-controlled double-blind study in 19 patients 
showed a significant improvement of swallowing function measured by ultrasound 
after the use of IvIg therapy.11
Non-invasive interventions include diet modification, compensatory techniques and 
feeding strategies. In case of failure of above mentioned therapeutic options a percu-
taneous endoscopic gastrostomy (PEG) tube placement can be required to warrant a 
sufficient calorie-intake.
We found a high rate of swallowing dysfunction in sporadic IBM patients. Patients 
however often do not report their dysphagia to their physicians resulting in inadequate 
treatment. Therefore, physicians should take a proactive approach in detecting swal-
lowing dysfunction. Detection of dysphagia is easy and feasible in a clinical setting, as 
well as useful as therapeutic interventions are available and life-threatening complica-
tions can be prevented.
Whether the heart, a non-skeletal striated muscle, is part of the disease was inves-
tigated in 51 sporadic IBM patients and described in chapter four. Extensive cardiac 
evaluation, comprising cardiac history, physical (cardiac) examination, laboratory tests, 
electrocardiography and echocardiography were performed. As a result, we found 
sporadic IBM patients not to be more prone for cardiac abnormalities than would 
be the case in an age-matched population. We did however find a high frequency of 
elevated troponin-T levels in patients with otherwise normal electrocardiography and 
echocardiography (79%). Troponin-T is considered to be a marker for cardiac damage. 
It is expressed in regenerating skeletal muscle fibers as well. Troponin-I is also a marker 




muscle fi bers. We found elevati on of troponin-I in only one sporadic IBM pati ent, who 
did have cardiac abnormaliti es. This led us to the conclusion that elevati on of tropo-
nin-T in sporadic IBM pati ents does not necessarily suggest cardiac pathology. Fisher 
et al12 studied the signifi cance of raised troponin-T in eleven pati ents with diff erent 
kinds of myositi s and normal electrocardiography and echocardiography. This study 
included one sporadic IBM pati ent only. In 5 pati ents, without further specifi cati on of 
diagnosis, they performed gel-fi ltrati on chromatography and found that in these pa-
ti ents the troponin-T was comparable with the nature of troponin-T in acute coronary 
syndromes. They concluded that elevati on of troponin-T in myositi s pati ents refl ected 
subclinical myocarditi s. However, they did not measure the heart-specifi c troponin-I 
levels and it is not clear whether the gel-fi ltrati on chromatography was performed 
in the one parti cipati ng sporadic IBM pati ent. Therefore, evidence that elevati on of 
troponin-T in sporadic IBM pati ents is of cardiac origin and therefore refl ects cardiac 
pathology is not yet available.
In contrast to our fi ndings, Utz et al. do report one atypical case of sporadic IBM with 
cardiac involvement.13 This case report describes a 36-year-old female pati ent with 
the diagnosis sporadic IBM made in her mid-twenti es, based on a muscle biopsy. She 
presented with acute onset exerti onal chest pain. Cardiovascular magneti c resonance 
revealed hypokineti c wall moti on of the left  ventricular wall. Furthermore, extensive 
pericardial fat was found. According to the authors this would be the fi rst case de-
scripti on of cardiac involvement in a sporadic IBM pati ent. This is an unusual age of 
presentati on of sporadic IBM, which casts doubt on the diagnosis.
In conclusion, as no other evidence has been found for cardiac involvement in 
sporadic IBM it is safe to conclude that it is not necessary to conduct routi ne cardiac 
investi gati ons in sporadic IBM pati ents.
The objecti ve of chapter fi ve was to describe the skeletal muscle abnormaliti es on MR 
imaging in 32 sporadic IBM pati ents. The additi onal value of MR imaging in the diag-
nosti c work-up in sporadic IBM was discussed. A total of 68 muscles in the upper and 
lower extremity were scored for fatt y infi ltrati on, infl ammati on (edema-like changes) 
and atrophy. We found a specifi c patt ern in our pati ent group. The presence of fat was 
far more pronounced than the presence of infl ammati on. Asymmetry of abnormaliti es 
was present in 44% of pati ents. Furthermore, a preference of fatt y infi ltrati on for cer-
tain muscles or muscle groups was seen. We found the quadriceps muscles to be com-
monly invaded with fat, with a relati ve sparing of the rectus femoris. Hamstrings and 
adductor muscles of the upper leg were spared compared to the quadriceps muscles, 
as well as sparing of the other pelvic girdle muscles. The fl exor digitorum profundus 
(FDP) was the most affl  icted muscle in the forearm. This selecti ve patt ern of muscle 
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involvement confirmed the findings of a smaller group of sporadic IBM patients previ-
ously described.14 If the FDP was not invaded with fat, other muscles of the forearm 
were normal as well. In the lower legs, the medial head of the gastrocnemius muscle 
was most commonly affected. Selective sparing of the rectus femoris and infliction of 
the medial head of the gastrocnemius muscle has also been described earlier in Becker 
muscular dystrophy.15 However, the same study shows clear affliction of the adductors 
and hamstring muscles in Becker patients in contrast to sporadic IBM patients. The 
number of muscles invaded with fat correlated well with disease duration in sporadic 
IBM. In contrast, inflammation of muscles did not correlate with disease duration and 
could be prominent even 10 years after onset of the disease. Based on this study we 
hypothesized inflammation to precede fatty infiltration of muscle, as inflammatory 
changes were mostly present in muscles which were relatively fat-free. However, as 
this was a cross-sectional study a follow-up study will be needed to clarify the time-
frame in which muscles become inflamed or infiltrated with fat.
We concluded that MR imaging of skeletal muscles in sporadic IBM showed a distinct 
pattern, which could be helpful for its diagnosis, especially in patients with a high 
clinical suspicion, but lacking the mandatory set of muscle biopsy features. however, 
MR imaging series of patients with other myopathies evaluated in a systematic way 
and compared to IBM patients are still lacking, and imaging of the forearm is not 
standard practice in other myopathies. Therefore, at the moment MR imaging cannot 
be decisive for the diagnosis of sporadic IBM.
In the sixth chapter, we investigated whether TREX1, a gene associated with a number 
of autoimmune diseases, was associated with sporadic IBM. If so, it could be a clue in 
finding a pathway that contributes to the pathophysiology. TREX1 is a protein which 
is involved in repair of damaged DNA. Research in mice showed that TREX1 deficiency 
led to accumulation of ssDNA in the cytoplasm, triggering an autoimmune response. 
We screened 54 sporadic IBM patients for presence of mutations in the TREX1 gene by 
direct sequencing. All patients tested negative for pathogenic mutations in the TREX1 
gene. therefore, an important role of TREX1 mutations in the pathogenesis of sporadic 
IBM seems highly unlikely.
Perspectives for the future
During the natural history study, it became clear that a significant part of the patients 




practi ti oner. They regarded a visit to a neurologist physically challenging, and rea-
soned that there was no treatment available anyway. Our studies, however, indicate 
that there are complicati ons in the course of sporadic IBM that can be treated, but 
are easily overlooked, especially by those not familiar with the disease. Dysphagia is a 
frequent and socially invalidati ng symptom that can be easily detected and someti mes 
treated successfully. If not specifi cally asked for it can be overlooked. Furthermore, the 
severe disability which can be present at the end stage of the disease must be recog-
nized in order to off er appropriate palliati ve care. Some pati ents menti oned that they 
had asked their general practi ti oner about end-of-life care interventi ons, but that they 
felt misunderstood. Therefore, it seems desirable to organize care for pati ents with 
sporadic IBM in neuromuscular centers, where these topics can be discussed in an ap-
propriate manner. Furthermore, respiratory disorders are a common cause of death in 
sporadic IBM. A few small studies report hypoventi lati on in sporadic IBM pati ents due 
to weakness of respiratory musculature. Whether disease burden is actually increased 
by hypoventi lati on is not yet known. Additi onally, whether non-invasive venti lati on 
can improve quality of life in these pati ents, as in pati ents with amyotrophic lateral 
sclerosis16 needs to be investi gated.
At this moment, MR imaging of muscles can be of additi onal value in the diagnosti c 
process in sporadic IBM pati ents with muscle weakness for several years. It is unclear 
however whether a specifi c patt ern is present at disease onset. It would be impor-
tant to analyze MR images of muscles in the early phase of the disease, to fi nd out 
if infl ammati on is more prominent in the beginning and whether the specifi c patt ern 
of fatt y infi ltrati on is already present. Furthermore, informati on about the degree of 
infl ammati on and fatt y infi ltrati on on MR imaging in the beginning of the disease could 
provide insight into the usefulness of MRI as an outcome measure in future clinical 
trials. Informati on about the rate of fatt y infi ltrati on could also be useful in pati ent 
selecti on for clinical trials, as pati ents early in the disease process, with the least fat 
infi ltrated muscles, are most amenable candidates for these trials.
Another outcome measure for clinical trials could be the measurement of weak-
ness progression in the quadriceps femoris muscle by quanti tati ve muscle testi ng. 
This muscle is frequently aff ected in the early stages of the disease, the progression 
of weakness is one of the fastest and weakness of this muscle results evidently in a 
decline of functi onal status.
The greatest challenge for clinical trials would be to include pati ents in the early 
phase of the disease. The degree of fatt y infi ltrati on in these pati ents is not prominent 
and therefore a clinically signifi cant eff ect of therapy is more likely to be found in these 
pati ents than in pati ents with extensive weakness due to fatt y replacement of muscles
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To include patients earlier, diagnosis of sporadic IBM must be made earlier. Whether 
MR imaging guided biopsies in sporadic IBM can be of additional value is not known 
yet. Furthermore, whether sporadic IBM biomarkers, such as the recently discovered 
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De sporadische vorm van inclusion body myositis (IBM) komt zelden voor, maar is toch 
de meest voorkomende spierziekte waarbij de eerste symptomen na het vijftigste 
levensjaar ontstaan. Mannen worden vaker door de ziekte getroffen dan vrouwen. 
Meestal begint de zwakte in de quadriceps spieren, de buigers van de vingers en de 
spieren die bij het slikken betrokken zijn. Zwakte van deze slikspieren veroorzaakt 
slikstoornissen. Ten gevolge van diagnostische valkuilen wordt de diagnose vaak laat 
gesteld. De pathogenese van sporadische IBM blijft tot op heden een raadsel, waarbij 
het onduidelijk is of de ziekte primair degeneratief dan wel auto-immuun is.
Aan het begin van dit onderzoek was er een gebrek aan informatie ten aanzien van het 
beloop van de ziekte over een lang tijdsbestek. In het tweede hoofdstuk van dit proef-
schrift worden de resultaten beschreven van een follow-up studie bij 64 patiënten 
met sporadische IBM. het doel van deze studie was om de snelheid van achteruitgang 
en de daarmee gepaard gaande verdeling van spierzwakte te beschrijven in de loop 
van meerdere jaren, evenals de daarbij komende beperkingen. Daarnaast werden de 
levensverwachting en doodsoorzaken beschreven. Er werd gezocht naar patiëntge-
bonden kenmerken met een mogelijk verband met het ziektebeloop.
Zoals verwacht bleek er sprake te zijn van een toenemend krachtsverlies, met een 
gemiddelde afname van spierkracht van 3.5% per jaar en 28.8% in 10 jaar tijd. Hierbij 
werd de kracht handmatig getest, gebruik makend van de MRC-schaal. Bij testen van 
de kracht door middel van een kwantitatieve schaal met behulp van een handdynamo-
meter vallen deze cijfers iets hoger uit, te weten 5.4% en 39.4%. Bijna alle patiënten 
gaven tijdens het onderzoek aan dat de zwakte geleidelijk en vrij uniform afnam, 
zonder plotse versnellingen. Een deel van de totale patiëntengroep nam tevens deel 
aan een ander onderzoek, waarbij het krachtsverlies in dit onderzoek na 50 weken 
vergelijkbaar was met het door ons berekende krachtsverlies. Een recent gepubliceerd 
artikel waarbij krachtsverlies bij 66 sporadische IBM patiënten werd onderzocht met 
de handdynamometer, beschrijft een gemiddeld krachtsverlies van 0.79% per maand.1 
Dit zou neerkomen op 9.1% per jaar, veel meer dan ons resultaat (5.4%). In het bo-
vengenoemde onderzoek werden vier spiergroepen getest (biceps, triceps, iliopsoas 
en quadriceps) in tegenstelling tot 14 spiergroepen in ons onderzoek. Als we de vier 
spiergroepen zouden selecteren die in Lindberg’s onderzoek gebruikt werden, dan 
zou het krachtsverlies in onze patiëntengroep 9.4% per jaar zijn. Onlangs beschreven 
Cortese et al. een gemiddeld krachtsverlies van 5.2% per jaar bij 23 patiënten, waar 
23 spiergroepen handmatig werden gemeten met behulp van de MRC-schaal.2 Aan 
geen van de onderzochte patiëntgebonden kenmerken kon een prognostische waarde 
worden toegezegd, zoals ook Lindberg en Cortese concludeerden.1, 2
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De spieren in de onderbenen verzwakten het snelst, gevolgd door de spieren in 
de onderarmen en de bovenbenen. Aan het begin van de ziekte waren de ventrale 
spieren meer aangedaan dan de dorsale. Deze verdeling verdween uiteindelijk in de 
onderbenen. De ernst van het krachtsverlies bleek uit de gebruikte functieschalen, 
waarmee werd aangetoond dat 40% van de patiënten na 20 jaar ziekte ernstig of 
geheel afhankelijk waren. Een rolstoel werd na gemiddeld 16 jaar ziekte voor het 
eerst gebruikt. Dit werd bevestigd door twee andere onderzoeken.2, 3 De aanname 
dat het geleidelijke en matige krachtsverlies in sporadische IBM niet leidt tot ernstige 
beperkingen in het dagelijks leven werd met onze studie weerlegd, en door Cortese 
bevestigd.2
De levensverwachting in sporadische IBM bleek niet verkort in onze patiëntengroep. 
Dit wordt bevestigd door twee recent verschenen onderzoeken.1, 3 De doodsoorzaken 
bij patiënten met sporadische IBM verschilden echter wel significant met die van de 
voor de leeftijd gecorrigeerde Nederlandse populatie: patiënten met sporadische 
IBM overleden vaker ten gevolge van aandoeningen aan het ademhalingssysteem, 
voornamelijk een (aspiratie) pneumonie. Mogelijk is dit een uiting van zwakte van 
ademhalingsspieren en/of faryngeale zwakte. Inamori et al. verrichtten een autop-
sie bij een patiënt met sporadische IBM, waarbij ontsteking en gerande vacuolen in 
het diafragma werden aangetroffen.4 ten gevolge van zwakte van de ademhalings-
spieren, waaronder mogelijk ook zwakte van de abdominale spieren, is het mogelijk 
dat patiënten niet goed kunnen doorademen, ophoesten en slikken wat kan leiden 
tot verslikking en uiteindelijk een (aspiratie)pneumonie. Een verhoogde prevalentie 
van pneumonieën ten gevolge van aspiratie bij sporadische IBM patiënten is eerder 
beschreven.5 Oh onderzocht 19 patiënten gedurende 50 maanden. Dertien overleden 
gedurende de follow-up periode, waarvan acht ten gevolge van een aspiratiepneu-
monie. De doodsoorzaak bij de anderen was onbekend. Cachexie werd relatief vaak 
gezien als doodsoorzaak in onze patiëntengroep. Dit weerspiegelt de invloed die het 
spierverval en de slikstoornissen in een vergevorderd stadium van de ziekte hebben. 
Daarnaast is er vaak gebruikt gemaakt van euthanasie (6.5%) en palliatieve sedatie 
(6.5%). Deze percentages komen in de buurt van het percentage interventies rond het 
levenseinde bij amytrofische laterale sclerose in Nederland.6 Deze cijfers onderstrepen 
de ziektelast in het late stadium van sporadische IBM des te meer.
Het effect van de immunosupressor methotrexaat gedurende 48 weken op de spier-
zwakte in een deel van onze patiëntengroep was verwaarloosbaar. Benvensite et al.3 
bevestigen dat behandeling met immunosuppressiva het verlies aan kracht niet remt. 
Zij verrichtten een observationeel onderzoek bij 136 sporadische IBM patiënten. Een-
enzeventig patiënten werden gedurende een mediane duur van 41 weken behandeld 
met immunosuppressiva, waarvan prednison het meest frequent. Tijdens het laatste 
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onderzoek bleek dat behandelde patiënten slechter scoorden op diverse functiescha-
len vergeleken met patiënten die geen immunosuppressiva hadden gebruikt. Lindberg 
et al.1 concluderen daarentegen dat patiënten met sporadische IBM, behandeld met 
diverse soorten immunosuppressiva, minder toename van zwakte in de biceps hadden 
dan onbehandelde patiënten. Deze conclusie is echter gebaseerd op een retrospectieve 
en niet-geblindeerde dataverzameling. Daarnaast bleek de toename van zwakte in de 
quadriceps niet beïnvloed te worden door het gebruik van immunosuppressiva, terwijl 
deze spier in onze studie juist het meeste krachtsverlies vertoonde. tevens gebruikten 
de patiënten in deze studie diverse soorten immunosuppressiva. In de onderzoeks-
groep zijn zelfs twee patiënten overleden ten gevolge van complicaties gerelateerd 
aan het gebruik van immunosuppressieve medicatie. De rol van immunosuppressieve 
behandeling bij sporadische IBM zou dan ook beperkt moeten zijn, zolang er geen 
duidelijk positief effect is aangetoond in een juist uitgevoerd klinisch onderzoek.
Ons onderzoek bracht de hoge ziektelast aan het licht, veroorzaakt door het chro-
nisch progressieve krachtsverlies. Sporadische IBM patiënten zijn weliswaar ambulant 
en zelfstandig in het begin van hun ziekte maar het eindstadium wordt gekenmerkt 
door ernstige invaliditeit. Bovendien brengt de normale levensverwachting een lang-
durige ziektelast met zich mee, waarbij beperkingen het dagelijks leven zeer nadelig 
beïnvloeden.
het derde hoofdstuk beschrijft de frequentie en aard van de bij sporadische IBM 
voorkomende slikstoornissen, evenals een methode waarmee slikstoornissen kunnen 
worden opgespoord. Zevenenvijftig patiënten werden ondervraagd met een vragenlijst 
gericht op slikklachten. Drieënveertig van deze patiënten werden eveneens onderzocht 
door middel van een slikvideofluoroscopie (VFS). Het doel was om de frequentie van 
slikstoornissen in sporadische IBM en de daarbij behorende symptomen te beschrijven 
en om specifieke vragen uit de vragenlijst te identificeren die slikstoornissen op de VFS 
konden voorspellen. Daarnaast werd getracht het mechanisme achter de slikstoornis-
sen bij sporadische IBM beter te begrijpen. Vijfenzestig procent van de 57 patiënten 
had slikklachten. Opmerkelijk genoeg had slechts een klein deel van deze patiënten 
hun klacht ooit met een arts besproken. twee vragen uit de vragenlijst konden slik-
stoornissen op de VFS goed voorspellen. Deze vragen waren: ‘Moet u meerdere malen 
slikken om eten te laten passeren’ en ‘Blijft er voedsel in uw keel hangen’.
De aard van de slikstoornis werd door middel van de VFS onderzocht. In 79% van de 
patiënten bleek de VFS afwijkend. De meest gevonden afwijkingen waren gerelateerd 
aan verminderde propulsie van de bolus, zoals dysfunctie van de cricofaryngeale 
sfincter. Tekenen gerelateerd aan aspiratie werden in bijna de helft van de patiënten 
gevonden, maar daadwerkelijke aspiratie werd nauwelijks geobserveerd. Cricofaryn-
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geale dysfunctie kwam veel voor, zoals ook beschreven werd in een ander onderzoek 
dat slikstoornissen in sporadische IBM onderzocht.5 Murata et al.7 onderzochten tien 
patiënten met sporadische IBM, met en zonder slikklachten. Zij verrichtten VFS en 
faryngoesofageale manometrie. Alle patiënten, inclusief de patiënten zonder slikklach-
ten, hadden cricofaryngeale dysfunctie. De faryngoesofageale manometrie liet tevens 
een vermindering van orofaryngeale peristaltische activiteit zien in alle patiënten, met 
afwezigheid van relaxatie van de cricofaryngeale sfincter in de patiënten met slikklach-
ten. Gebaseerd op de huidige kennis worden slikstoornissen in sporadische IBM meest 
waarschijnlijk veroorzaakt door zwakte van de farynxspieren, waarbij er onvoldoende 
druk wordt gegenereerd om de cricofaryngeale sfincter te laten ontspannen. Deze 
slechte samenwerking tussen de aanspannende farynxspieren en de sfincter veroor-
zaken stase van de bolus in de farynx. Behandeling van slikklachten is onderverdeeld 
in invasieve en conservatieve maatregelen. Invasieve maatregelen zijn cricofaryngeale 
myotomie, welke het meest wordt toegepast, en faryngoesofagale dilatatie. Cricofa-
ryngeale myotomie lijkt een succesvolle behandeling in 63% van de sporadische IBM 
patiënten, terwijl faryngoesofagale dilatatie minder effectief lijkt (33%).5 Een reden 
voor falen van therapie zou een te ver gevorderde zwakte van de farynxspieren kunnen 
zijn. Het is vastgesteld dat langdurige obstructie van de faryngoesofagale doorgang 
leidt tot zwakte van de farynxspieren.8 Daarom is het te verdedigen om patiënten te 
behandelen als slikstoornissen nog niet in een ver gevorderd stadium zijn, om een 
optimaal resultaat van de behandeling te verkrijgen. Het effect van behandeling kan 
mogelijk worden voorspeld door de intra-bolus druk vast te stellen, een meting die 
de faryngeale kracht reflecteert, maar onderzoek hiernaar is nog niet voor handen. 
Botuline toxine injecties in de cricofaryngeale sfincter is een andere invasieve behan-
delmethode, maar onderzoek naar de effectiviteit hiervan ontbreekt tot op heden. 
Enkele case reports beschrijven een positief effect op de slikfunctie van intraveneuze 
immunoglobuline (IvIg) therapie.9, 10 Daarnaast toonde een placebo-gecontroleerd 
dubbelblind onderzoek bij 19 patiënten een verbetering van de slikfunctie, vastgesteld 
met echografie, na het gebruik van IvIg.11
Conservatieve behandelingen zijn aanpassingen in het dieet en het toepassen van 
compensatoire slikbewegingen. Indien de bovengenoemde therapieën falen, kan 
plaatsing van een PEG-sonde (percutane endoscopische gastrostomie) nodig zijn om 
voldoende (calorische) inname van voedsel te waarborgen.
Uit huidig onderzoek is gebleken dat slikklachten een frequent probleem vormen 
in patiënten met sporadische IBM. Patiënten melden hun slikklachten echter niet 
spontaan, wat kan resulteren in een suboptimale behandeling. Daarom moeten artsen 
een proactieve aanpak hebben in het detecteren van slikklachten. Het vaststellen van 
slikstoornissen in de spreekkamer is makkelijk en mogelijk, en omdat therapeutische 
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interventies voor handen zijn ook nuttig. Levensbedreigende complicaties kunnen 
hierdoor beperkt worden.
Of het hart, net als de skeletspier ook een dwarsgestreepte spier, ook wordt beïn-
vloedt door de ziekte, is onderzocht in 51 patiënten met sporadische IBM en wordt 
beschreven in hoofdstuk 4. Uitgebreid cardiaal onderzoek werd verricht, zoals afname 
van cardiale voorgeschiedenis, lichamelijk (cardiaal) onderzoek, bloedonderzoek, een 
elektrocardiogram en echocardiogram. Dit resulteerde in de bevinding dat sporadi-
sche IBM patiënten niet meer risico lopen op cardiale aandoeningen dan een voor de 
leeftijd gecorrigeerde populatie. Wel vonden we frequent een verhoogd troponine-T in 
patiënten met een normaal elektrocardiogram en echocardiogram (79%). Troponine-T 
wordt beschouwd als een marker voor cardiale schade. het wordt echter ook tot ex-
pressie gebracht in regenererende skeletspieren. troponine-I is ook een marker voor 
cardiale schade maar wordt, in tegenstelling tot troponine-t, niet tot expressie ge-
bracht in regenererende skeletspiervezels. troponine-I verhoging werd in slechts één 
sporadische IBM patiënt gevonden. Deze patiënt had wel degelijk cardiale afwijkingen. 
Dit heeft tot de conclusie geleid dat verhoging van troponine-T in patiënten met 
sporadische IBM zelden duidt op cardiale pathologie. Fisher et al.12 bestudeerden de 
waarde van verhoogd troponine-T in 11 patiënten met verschillende soorten myositis 
met een normaal elektrocardiogram en echocardiogram. In dit onderzoek was slechts 
één patiënt met sporadische IBM geïncludeerd. In vijf patiënten, zonder duidelijke 
specificatie van de diagnose, werd gelfiltratie chromatografie toegepast. Hieruit bleek 
dat bij deze patiënten het troponine-T vergelijkbaar was met het troponine-T bij het 
acuut coronair syndroom. Er werd geconcludeerd dat verhoging van troponine-t in pa-
tiënten met myositis wijst op een subklinische myocarditis. Echter, het hart-specifieke 
troponine-I werd niet bepaald en het is ook niet duidelijk of de patiënt met sporadische 
IBM deel uitmaakte van het onderzoek. het bewijs dat troponine-t in sporadische IBM 
van cardiale oorsprong is en dus wijst op cardiale pathologie is nog niet voor handen.
Enigszins in tegenspraak met onze bevindingen, beschrijven Utz et al. een casus van 
een atypische sporadische IBM patiënt met cardiale betrokkenheid.13 In dit verslag 
wordt een 36 jarige vrouw beschreven, die de diagnose sporadische IBM in haar twin-
tiger jaren heeft gekregen, gebaseerd op een spierbiopt. Ze kreeg klachten van acute 
pijn op de borst bij inspanning. Een cardiovasculaire MRI toonde een hypokinetische 
linker kamer. Daarnaast werd uitgebreid pericardiaal vet aangetroffen. Volgens de 
auteurs zou dit de eerste casusbeschrijving zijn van cardiale betrokkenheid bij spo-
radische IBM. Deze debuutleeftijd is een ongewoon voor sporadische IBM, wat doet 
twijfelen aan de diagnose.
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Afgezien van deze ene, atypische casusbeschrijving is er geen ander bewijs voor car-
diale betrokkenheid bij sporadische IBM is gevonden. Om deze reden is het niet nodig 
om standard cardiaal onderzoek te verrichten bij patiënten met sporadische IBM.
het doel van het onderzoek in hoofdstuk 5 was om MRI afwijkingen van skeletspieren 
te beschrijven bij 32 sporadische IBM patiënten. De toegevoegde waarde van MRI in 
het diagnostisch proces van sporadische IBM wordt besproken. In totaal werden 68 
spieren van de armen en benen beoordeeld op vervetting, ontsteking (oedeemvor-
ming) en atrofie. We vonden een specifiek patroon in onze patiëntengroep. Vervetting 
was meer uitgesproken aanwezig dan ontsteking. Asymmetrie van afwijkingen werd 
in 44% van de patiënten gezien. De vervetting bleek bij bepaalde spieren en spier-
groepen een speciale voorkeurslokalisatie te hebben. De quadriceps was de meest 
vervette spier, met relatief gespaard blijven van de rectus femoris. De hamstrings en 
de adductoren van de bovenbenen waren ook relatief gespaard vergeleken met de 
quadriceps, net zoals de andere bekkengordelspieren. De flexor digitorum profundus 
(FDP) was de meest aangedane spier in de onderarm. Dit selectieve patroon van ver-
vetting is eerder beschreven in een kleinere groep sporadische IBM patiënten.14 Als de 
FDP niet was vervet, dan zagen de andere onderarmspieren er ook normaal uit. In de 
onderbenen zat de vervetting vooral in de mediale kop van de gastrocnemius. Eerder 
werd een selectieve sparing van de rectus femoris in combinatie met vervetting van de 
mediale kop van de gastrocnemius beschreven bij de spierdystrofie van Becker.15 In dat 
onderzoek wordt echter ook beschreven dat juist de adductoren van de bovenbenen 
en de hamstrings duidelijk zijn vervet bij de patiënten met Becker spierdystrofie, dit in 
tegenstelling tot patiënten met sporadische IBM.
Bij sporadische IBM correleert het aantal vervette spieren goed met de ziekteduur. 
Het aantal spieren met onstekingsachtige verschijnselen correleert niet goed met 
de ziekteduur en zelfs na een ziekteduur van 10 jaar kunnen spieren nog duidelijke 
tekenen van ontsteking vertonen. Gebaseerd op dit onderzoek vermoeden wij dat bij 
sporadiche IBM ontsteking voorafgaat aan vervetting, aangezien de ontsteking vooral 
werd gezien in relatief vetvrije spieren. Dit was echter een dwarsdoorsnede onderzoek; 
met een follow-up onderzoek zou beter kunnen vastgesteld kunnen worden binnen 
welk tijdsbestek de spieren ontstoken en vervet raken.
Wij concludeerden dat MRI afwijkingen van de skeletspieren in sporadische IBM een 
duidelijk patroon laten zien, wat een indicatie voor de diagnose zou kunnen zijn. Vooral 
bij patiënten met een hoge klinische verdenking, maar waarbij de nodige criteria van 
het spierbiopt ontbreken.
Systematische MRI onderzoeken die sporadische IBM patiënten met patiënten met 
andere myopathieën vergelijken ontbreken echter nog. In het bijzonder is het afbeel-
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den van de onderarm niet standaard bij andere myopathieeën. MRI kan daarom nog 
niet ingezet worden als middel om de diagnose sporadische IBM te stellen.
In hoofdstuk 6 onderzochten we of TREX1, een gen dat geassocieerd is met een 
aantal auto-immuun ziekten, geassocieerd is met sporadische IBM. Deze informatie 
zou ons verder kunnen brengen in de zoektocht naar de pathogenese. tREX1 is een 
eiwit dat betrokken is in het herstel van beschadigd DNA. Onderzoek bij muizen heeft 
aangetoond dat een tekort aan tREX1 leidt tot ophoping van ssDNA in het cytoplasma, 
wat op zijn beurt een immuunreactie teweeg brengt. We hebben 54 patiënten met 
sporadische IBM gescreend op de aanwezigheid van mutaties in het TREX1 gen door 
middel van de directe sequentie methode. Geen enkele patiënt had een pathologische 
mutatie in het TREX1 gen. Een belangrijke rol van TREX1 mutaties in de pathogenese 
van sporadische IBM is daarom onwaarschijnlijk.
Toekomstperspectieven
Gedurende het onderzoek met betrekking tot het natuurlijk beloop werd duidelijk dat 
een groot deel van de patiënten niet meer onder controle was bij hun eigen neu-
roloog, maar voor vragen de huisarts consulteerde. Ze vonden een bezoek aan het 
ziekenhuis een fysieke uitdaging, waarbij ze aangaven dat er toch geen behandeling 
voorhanden was. Uit onderzoek is echter gebleken dat er complicaties in het beloop 
van de ziekte op kunnen treden die weldegelijk behandeld kunnen worden. Deze com-
plicaties kunnen echter gemakkelijk over het hoofd worden gezien, in het bijzonder 
bij artsen die niet goed bekend zijn met de ziekte. Slikklachten zijn een frequent en 
sociaal invaliderend probleem welke eenvoudig kunnen worden vastgesteld en soms 
succesvol worden behandeld. Als er niet specifiek naar wordt gevraagd, kunnen deze 
gemist worden.
Daarnaast moet de ernstige invaliditeit die optreedt in het latere ziektestadium 
onderkend worden, zodat palliatieve zorg bespreekbaar wordt gemaakt. Enkele pa-
tiënten meldden dat zij hun euthanasiewens met de huisarts hadden besproken, 
maar dat zij zich onbegrepen voelden. hierdoor is het ook belangrijk om de zorg voor 
patiënten met sporadische IBM te organiseren in neuromusculaire centra, waar deze 
onderwerpen op een gepaste manier besproken kunnen worden.
Aandoeningen van het ademhalingsstelsel zijn een vaak voorkomende doodsoor-
zaak in sporadische IBM. Enkele kleine onderzoeken beschrijven hypoventilatie in 
patiënten met sporadische IBM ten gevolge van zwakte van de ademhalingsspieren. 
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Of de ziektelast door de hypoventilatie wordt vergroot is nog niet bekend, evenals de 
vraag of niet-invasieve ventilatie de kwaliteit van leven zou kunnen verbeteren in deze 
patiënten, zoals soms het geval is bij patiënten met amyotrofische laterale sclerose.16 
Dit zou nog onderzocht moeten worden.
Op dit moment kan een MRI van de spieren van aanvullende waarde zijn in het 
diagnostisch proces bij sporadische IBM patiënten met al enkele jaren aanwezige 
spierzwakte. Het is echter niet duidelijk of er ook een specifiek afwijkend patroon 
aanwezig is bij de aanvang van de ziekte. het is belangrijk om de spieren door middel 
van MRI te bestuderen in de beginfase van de ziekte, om te beoordelen of ontsteking 
meer prominent aanwezig is in de beginfase van de ziekte en of het specifieke patroon 
van vervetting dan al aanwezig is. Daarnaast zou kennis over de mate van ontsteking 
en vervetting op de MRI in de beginfase van de ziekte inzicht kunnen verschaffen over 
het nut van MRI als een uitkomstmaat in clinical trials. Informatie over de mate van de 
vervetting zou ook nuttig kunnen zijn voor deze clinical trials, aangezien patiënten in de 
beginfase de minst vervette spieren hebben en hierop kunnen worden geselecteerd.
Een andere uitkomstmaat voor klinische onderzoeken zou het meten van de zwakte 
van de quadriceps femoris door middel van de handdynamometer kunnen zijn. Deze 
spier is vaak aangedaan in het begin van de ziekte, de progressie van de zwakte in deze 
spier is een van de snelste en zwakte van deze spier leidt tot een evidente daling van 
de functionele status.
De grootste uitdaging voor klinische trials is om patiënten te includeren die in het 
beginstadium van de ziekte zijn. De spiervervetting in deze patiënten is nog spaarzaam 
en daardoor zou een significant effect van therapie bij deze patiënten waarschijnlijker 
zijn dan bij patiënten met uitgebreide vervetting en zwakte. Om patiënten eerder te 
kunnen includeren, moet de diagnose sporadische IBM makkelijker gesteld kunnen 
worden. Of MRI geleide spierbiopten hierbij van aanvullende waarde zijn is nog niet 
bekend. Daarnaast moet nog afgewacht worden of biomarkers bij sporadische IBM, 




 1. Lindberg C, Oldfors A. Prognosis and prognostic factors in sporadic inclusion body myositis. Acta Neurol 
Scand 2012;125(55):353-358.
 2. Cortese A, Machado P, Morrow J et al. Longitudinal observational study of sporadic inclusion body 
myositis: implications for clinical trials. Neuromuscul Disord 2013;23(5):404-412.
 3. Benveniste O, Guiguet M, Freebody J et al. Long-term observational study of sporadic inclusion body 
myositis. Brain 2011;134(Pt 11):3176-3184.
 4. Inamori Y, Higuchi I, Inoue T et al. Inclusion body myositis coexisting with hypertrophic cardiomyopa-
thy: an autopsy study. Neuromuscul Disord 2012;22(8):747-754.
 5. Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR. Dysphagia in inclusion body myositis: 
clinical features, management, and clinical outcome. Am J Phys Med Rehabil 2008;87(11):883-889.
 6. Veldink JH, Wokke JH, van der WG, Vianney de Jong JM, van den Berg LH. Euthanasia and physician-
assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands. N Engl J Med 
2002;346(21):1638-1644.
 7. Murata KY, Kouda K, Tajima F, Kondo T. A dysphagia study in patients with sporadic inclusion body 
myositis (s-IBM). Neurol Sci 2012;33(4):765-770.
 8. Belafsky PC, Rees CJ, Allen J, Leonard RJ. Pharyngeal dilation in cricopharyngeus muscle dysfunction 
and Zenker diverticulum. Laryngoscope 2010;120(5):889-894.
 9. Cherin P, Pelletier S, Teixeira A et al. Intravenous immunoglobulin for dysphagia of inclusion body 
myositis. Neurology 2002;58(2):326.
 10. Pars K, Garde N, Skripuletz T, Pul R, Dengler R, Stangel M. Subcutaneous immunoglobulin treatment of 
inclusion body myositis stabilizes dysphagia. Muscle Nerve 2013.
 11. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myosi-
tis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48(3):712-716.
 12. Fisher C, Agrawal S, Wong WM, Fahie-Wilson M, Dasgupta B. Clinical observations on the significance 
of raised cardiac troponin-T in patients with myositis of varying etiologies seen in rheumatology prac-
tice. Clin Rheumatol 2010;29(10):1107-1111.
 13. Utz W, Schmidt S, Schulz-Menger J, Luft F, Spuler S. Cardiac involvement in sporadic inclusion-body 
myositis. Circulation 2010;121(5):706-708.
 14. Phillips BA, Cala LA, Thickbroom GW, Melsom A, Zilko PJ, Mastaglia FL. Patterns of muscle involve-
ment in inclusion body myositis: clinical and magnetic resonance imaging study. Muscle Nerve 
2001;24(11):1526-1534.
 15. de Visser M, Verbeeten B, Jr. Computed tomography of the skeletal musculature in Becker-type muscu-
lar dystrophy and benign infantile spinal muscular atrophy. Muscle Nerve 1985;8(5):435-444.
 16. Radunovic A, Annane D, Jewitt K, Mustfa N. Mechanical ventilation for amyotrophic lateral sclerosis/
motor neuron disease. Cochrane Database Syst Rev 2009;(4):CD004427.
 17. Pluk H, van Hoeve BJ, van Dooren SH et al. Autoantibodies to cytosolic 5’-nucleotidase 1A in inclusion 





Cox FM, Badrising UA, de Visser M, van Engelen B, Verschuuren JJGM. Inflammatory
myopathies. In: Neuromuscular Imaging. Ed. Wattjes&Fischer, Springer. In press
Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJGM, Badrising UA. A 12-year 
follow-up in sporadic inclusion body myositis: an end-stage with major disabilities. 
Brain 2011;134:3167-75
Cox FM, Reijnierse M, van Rijswijk CS, Wintzen AR, Veschuuren JJGM, Badrising UA.
Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. 
Rheumatology 2011;50:1153-61
Cox FM, Verschuuren JJ, Badrising UA. Clinical reasoning: A 70-year-old man with walk-
ing difficulties. Neurology 2010;75(19):e80-e84
Cox FM, Delgado V, Verschuuren JJ, Ballieux BE, Bax JJ, Wintzen AR, et al.
The heart in sporadic inclusion body myositis: a study in 51 patients.
J Neurol 2010;257(3):447-51
Cox FM, Boon EM, van der Lans CA, Bakker E, Verschuuren JJ, Badrising UA.
TREX1 mutations are not associated with sporadic inclusion body myositis.
Eur J Neurol 2010 ;17(8):1108-09
Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA.
Detecting dysphagia in inclusion body myositis. J Neurol 2009;256(12):2009-13
Cox FM, Verschuuren JJGM, Wintzen AR, Badrising UA.
Possible prognostic factors in the clinical course of patients with inclusion body myosi-
tis. Neuromusc Disord. 2008; 18:771
Cox FM, Verschuuren JJGM, Wintzen AR, Badrising, UA.
‘Inclusion-body’-myositis: de stand van zaken. Tijdschr Neurol Neurochir. 2008;109:238-44
Cox FM, Cornel JH, Aramideh M. A man with the combination of dry and wet beriberi.
Ned Tijdschr Geneeskd 2006;150(24):1347-50
106
LISt OF PUBLICAtIONS





Fieke Maria Elisabeth Cox is born in Oss on February 18th , 1979. In 1997 she obtained 
her ‘gymnasium’ diploma at the Titus Brandsma Lyceum in Oss. Afterwards, she stud-
ied Medicine at the University of Amsterdam. During her studies, she performed a 
research internship in Bangkok Thailand, investigating nephrotoxicity of Indinavir in 
combination with Ritonavir in HIV-positive patients. As part of her clinical internships, 
she worked at the department of Women’s health of the Nyerere Designated District 
hospital in Mugumu, Tanzania. In 2004, she obtained her Medical Degree. Afterwards, 
she joined the Department of Neurology of the Medical Center Alkmaar as an ‘AGNIO’ 
(Dr. R. ten Houten). In 2006 she commenced her residency in Neurology at Leiden 
University Medical Center (Prof. R.A.C. Roos). She joined the neuromuscular research 
group in 2008 to start the PhD project described (Prof J.J.G.M. Verschuuren). In 2012 
she received the annual award neuromuscular diseases by the “Prinses Beatrix Fonds’’ 
for her study concerning the natural history in sporadic IBM. In December 2011 she 
qualified as a neurologist and has worked as a neurologist at the ‘Zaans Medisch Cen-
trum’ and ‘Diaconessenhuis Leiden’. In August 2014 she started working at ‘Stichting 
Epilepsie Instellingen Nederland’(SEIN) as a neurologist and clinical neurophysiologist.
